var title_f2_19_2352="Map ectopic atrial tachycardia";
var content_f2_19_2352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic map of focal right atrial tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color-coded activation isochrones generated during an ectopic or focal atrial tachycardia show that the earliest activation, relative to a remote fiducial point, is the lower part of the right atrium, represented by red color. The spread of activation is centrifugal from a focal point located along the distal crista terminalis and goes from the lowest part towards the top of the right atrium (blue color).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hasan Garan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2352=[""].join("\n");
var outline_f2_19_2352=null;
var title_f2_19_2353="Accessory AV pathways II";
var content_f2_19_2353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53773&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AV conduction through an open accessory pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compared to normal conduction in the preceding diagram, the accessory pathway (AP) is now open. As a result, ventricular activation results from both early activation (preexcitation) of the free wall of the left ventricle (shown in blue) and from normal activation (shown in yellow). The degree of unopposed preexcitation depends upon the time required to conduct through the right and left atria, the AP, and the ventricular myocardium as compared to conduction through the normal pathways. The inset on the right shows the ECG timing of these events. The net effect is a QRS complex that is a fusion of ventricular preexcitation (blue) and normal excitation (yellow). Early activation throught the AP (V",
"    <sub>",
"     P",
"    </sub>",
"    ) occurs at about the same time as His bundle depolarization (H). This leads to a shorter PR interval, a small delta wave (arrow), and some prolongation of the QRS duration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2353=[""].join("\n");
var outline_f2_19_2353=null;
var title_f2_19_2354="CT IPMN parenchymal atrophy";
var content_f2_19_2354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography of intraductal papillary mucinous neoplasm with parenchymal atrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of main duct intraductal papillary mucinous neoplasm, revealing a markedly dilated pancreatic duct with parenchymal atrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin McGrath, MD, and Asif Khalid, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2354=[""].join("\n");
var outline_f2_19_2354=null;
var title_f2_19_2355="Isometric test supraspinatus";
var content_f2_19_2355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Isometric testing of the supraspinatus tendon in midarc",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This maneuver assesses the strength and integrity of the supraspinatus tendon. The patient's arm is abducted to 45 degrees. The patient is asked to actively abduct the arm against the resistance of the examiner's hand placed at the elbow. The effort, strength, and discomfort are noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2355=[""].join("\n");
var outline_f2_19_2355=null;
var title_f2_19_2356="Coal tar: Pediatric drug information";
var content_f2_19_2356=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Coal tar: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=see_link\">",
"    see \"Coal tar: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/51/13109?source=see_link\">",
"    see \"Coal tar: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Balnetar&reg; [OTC];",
"     </li>",
"     <li>",
"      Betatar Gel&reg; [OTC];",
"     </li>",
"     <li>",
"      Cutar&reg; [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Therapeutic Protection 2-in-1 Shampoo + Conditioner [OTC];",
"     </li>",
"     <li>",
"      Denorex&reg; Therapeutic Protection [OTC];",
"     </li>",
"     <li>",
"      DHS&reg; Tar [OTC];",
"     </li>",
"     <li>",
"      DHS&trade; Tar Gel [OTC];",
"     </li>",
"     <li>",
"      Exorex&reg; Penetrating Emulsion #2 [OTC];",
"     </li>",
"     <li>",
"      Exorex&reg; Penetrating Emulsion [OTC];",
"     </li>",
"     <li>",
"      ionil-T&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      ionil-T&reg; [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar Extra Strength [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar Intensive Strength [OTC];",
"     </li>",
"     <li>",
"      MG217&reg; Medicated Tar [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; Stubborn Itch Control [OTC];",
"     </li>",
"     <li>",
"      Neutrogena&reg; T/Gel&reg; [OTC];",
"     </li>",
"     <li>",
"      Oxipor&reg; VHC [OTC];",
"     </li>",
"     <li>",
"      Pentrax&reg; [OTC];",
"     </li>",
"     <li>",
"      Scytera&trade; [OTC];",
"     </li>",
"     <li>",
"      Tera-Gel&trade; [OTC];",
"     </li>",
"     <li>",
"      Thera-Gel [OTC];",
"     </li>",
"     <li>",
"      Zetar&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Doak Oil Forte [OTC];",
"     </li>",
"     <li>",
"      Doak Oil [OTC];",
"     </li>",
"     <li>",
"      Emorex Gel [OTC];",
"     </li>",
"     <li>",
"      Neuotrogena T/Gel Therapeutic Shampoo [OTC];",
"     </li>",
"     <li>",
"      Odans Liquor Carbonis Detergens [OTC];",
"     </li>",
"     <li>",
"      Pentrax Gold Shampoo [OTC];",
"     </li>",
"     <li>",
"      Pentrax Tar Shampoo [OTC];",
"     </li>",
"     <li>",
"      Psoriasin [OTC];",
"     </li>",
"     <li>",
"      T/Gel Therapeutic Shampoo Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Targel&reg; [OTC];",
"     </li>",
"     <li>",
"      Tersa Tar Shp [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsoriatic Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiseborrheic Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=see_link\">",
"      see \"Coal tar: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bath: 60-90 mL of a 5% to 20% solution or 15-25 mL of 30% lotion is added to bath water; soak 5-20 minutes, then pat dry; use once daily to once every 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Apply twice weekly for the first 2 weeks then once weekly or more often if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Skin: Apply to the affected area 1-4 times/day; decrease frequency to 2-3 times/week once condition has been controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atopic dermatitis: 2% to 5% coal tar cream may be applied once daily or every other day to reduce inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Scalp psoriasis: Tar oil bath or coal tar solution may be painted sparingly to the lesions 3-12 hours before each shampoo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Psoriasis of the body, arms, legs: Apply at bedtime; if thick scales are present, use product with salicylic acid and apply several times during the day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scytera&trade;: Coal tar solution 10% (100 g) [equivalent to coal tar 2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutar&reg;: Coal tar solution 7.5% (180 mL, 3840 mL) [equivalent to coal tar 1.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exorex&reg; Penetrating Emulsion: Coal tar 1% (100 mL, 250 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exorex&reg; Penetrating Emulsion #2: Coal tar 2% (100 mL, 250 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical [shampoo]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DHS&trade; Tar Gel: Solubilized coal tar extract 2.9% (240 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thera-Gel: 0.5% (255 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MG217&reg; Medicated Tar: Coal tar solution 5% (120 mL) [contains jojoba; equivalent to coal tar 1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxipor&reg; VHC: Coal tar solution 25% (56 mL, 120 mL) [contains ethanol 79%; equivalent to coal tar 5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Balnetar&reg;: Coal tar 2.5% (221 mL) [for use in bath]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MG217&reg; Medicated Tar Intensive Strength: Coal tar solution 10% (107 g) [equivalent to coal tar 2%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betatar Gel&reg;: Coal tar solution 12.5% (480 mL) [equivalent to coal tar 2.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denorex&reg; Therapeutic Protection: Coal tar solution 12.5% (118 mL, 240 mL, 300 mL) [contains ethanol 10.4%; equivalent to coal tar 2.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DHS&reg; Tar: Solubilized coal tar extract 2.9% (120 mL, 240 mL, 480 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ionil-T&reg;: Coal tar 1% (240 mL, 480 mL, 960 mL) [contains ethanol 12%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ionil-T&reg; Plus: Coal tar 2% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MG217&reg; Medicated Tar Extra Strength: Coal tar solution 15% (120 mL, 240 mL) [equivalent to coal tar 3%; with conditioners]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; T/Gel&reg;: Solubilized coal tar extract 2% (130 mL, 255 mL, 480 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; T/Gel&reg; Extra Strength: Solubilized coal tar extract 4% (177 mL) [equivalent to coal tar 1%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrogena&reg; T/Gel&reg; Stubborn Itch Control: Coal tar extract 2% (130 mL) [contains menthol; equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentrax&reg;: Coal tar 5% (236 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tera-Gel&trade;: Solubilized coal tar extract 2% (120 mL, 255 mL) [equivalent to coal tar 0.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zetar&reg;: Coal tar 1% (177 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo/Conditioner, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Denorex&reg; Therapeutic Protection 2-in-1 Shampoo + Conditioner: Coal tar solution 12.5% (120 mL, 240 mL, 300 mL) [contains ethanol 10.4%; equivalent to coal tar 2.5%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 20% (473 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bath: Add appropriate amount of coal tar to lukewarm bath water and mix thoroughly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Rub shampoo onto wet hair and scalp, rinse thoroughly; repeat; leave on 5 minutes; rinse thoroughly",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topically for controlling dandruff, seborrheic dermatitis, or psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pentrax [U.S., Canada, Great Britain, Ireland] may be confused with Permax brand name for pergolide [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F154039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dermatologic: Dermatitis, folliculitis, irritation, photosensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to coal tar or any ingredient in the formulation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not apply to acutely inflamed skin; avoid exposure to sunlight for at least 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to a potential carcinogenic risk, do not use around the rectum or in the genital area or groin",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13862032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limited application of coal tar during pregnancy for the treatment of psoriasis appears to be safe in pregnant women (Gelmetti, 2009; Landau, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces the number and size of epidermal cells produced",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/51/13109?source=see_link\">",
"      see \"Coal tar: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes, genital, or rectal area; coal tar preparations frequently stain the skin and hair; shake suspension well before use. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Greaves MW, Weinstein GD, &ldquo;Treatment of Psoriasis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(9):581-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2356/abstract-text/7838193/pubmed\" id=\"7838193\" target=\"_blank\">",
"        7838193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanifin JM, &ldquo;Atopic Dermatitis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):763-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2356/abstract-text/1870905/pubmed\" id=\"1870905\" target=\"_blank\">",
"        1870905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13175 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2356=[""].join("\n");
var outline_f2_19_2356=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154027\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154028\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046541\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046537\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154021\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154010\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046544\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046543\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154040\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154039\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046546\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046536\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046535\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299071\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219451\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13862032\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046534\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046540\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13175\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13175|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=related_link\">",
"      Coal tar: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/51/13109?source=related_link\">",
"      Coal tar: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_19_2357="Patient information: Breast cancer (The Basics)";
var content_f2_19_2357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15365\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/12/9412\">",
"         Lumpectomy and mastectomy to treat breast cancer",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/10/44193\">",
"         Patient information: Breast biopsy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/59/19379\">",
"         Patient information: Breast cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/62/11236\">",
"         Patient information: Breast reconstruction after mastectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/8/8321\">",
"         Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6115\">",
"         Patient information: Common breast problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/18/12579\">",
"         Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/59/6066\">",
"         Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/53/25426\">",
"         Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36481\">",
"         Patient information: Breast cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/52/26437\">",
"         Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/2/39970\">",
"         Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/6/44134\">",
"         Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/47/5875\">",
"         Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/32/15876\">",
"         Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/31/499\">",
"         Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/44/27335\">",
"         Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/11/27827\">",
"         Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Breast cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/breast-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H385344326\">",
"      <span class=\"h1\">",
"       What is breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breast cancer happens when normal cells in the breast change and grow out of control. Women sometimes discover they have breast cancer because they find a lump in one of their breasts. Breast cancer is much more common in women than in men. But men can get the disease. Breast cancer sometimes runs in families.",
"     </p>",
"     <p>",
"      If you feel a lump in your breast, see your doctor or nurse right away. Breast lumps can be caused by conditions that are not cancer. But it is a good idea to have any lumps checked out.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344333\">",
"      <span class=\"h1\">",
"       Is there a test for breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors use a special kind of x-ray called a mammogram to check for breast cancer. If a mammogram finds a spot that looks like it could be cancer, doctors usually follow up with another test called a biopsy. During a biopsy, a doctor takes one or more small samples of tissue from the breast. That way the doctor can look at the cells under a microscope to see if they have cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344340\">",
"      <span class=\"h1\">",
"       What is breast cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far a cancer has spread. The right treatment for you will depend, in part, on the stage of your cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344347\">",
"      <span class=\"h1\">",
"       How is breast cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with breast cancer have one or more of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Breast cancer is usually treated with surgery to remove the cancer. Many women with breast cancer can choose between mastectomy and breast conserving therapy (also called &ldquo;lumpectomy&rdquo;) (",
"        <a class=\"graphic graphic_figure graphicRef73172 \" href=\"UTD.htm?9/12/9412\">",
"         figure 1",
"        </a>",
"        ):",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <strong>",
"         Mastectomy",
"        </strong>",
"        is surgery to remove the whole breast. (If you choose this option, you might have to decide whether to have surgery to reconstruct your breast and when.)",
"       </li>",
"       <li>",
"        <strong>",
"         Breast conserving therapy",
"        </strong>",
"        (lumpectomy) is surgery to remove the cancer and a section of healthy tissue around it. Women who choose this option keep their breast. But they usually must have radiation therapy after surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Some women take these medicines before surgery to shrink the cancer and make it easier to remove. Some women take these medicines after surgery to keep cancer from growing, spreading, or coming back.",
"       </li>",
"       <li>",
"        <strong>",
"         Hormone therapy",
"        </strong>",
"        &ndash; Some forms of breast cancer grow in response to hormones. Your doctor might give you treatments to block hormones or to prevent your body from making certain kinds of hormones.",
"       </li>",
"       <li>",
"        <strong>",
"         Targeted therapy",
"        </strong>",
"        &ndash; Some medicines work only on cancers that have certain characteristics. Your doctor might test you to see if you have a kind of cancer that would respond to this kind of therapy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344354\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will need to be checked every so often to see if the cancer comes back. You will have tests, usually including more mammograms. You should also watch for symptoms that could mean the cancer has come back. Examples of these symptoms include new lumps in the breast area, pain (in the bones, chest, or stomach), trouble breathing, and headaches. If you start having any new symptom, mention it to your doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344361\">",
"      <span class=\"h1\">",
"       What happens if cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on where the cancer is. Most people get hormone therapy or chemotherapy. Some people also have surgery to remove new tumors.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344368\">",
"      <span class=\"h1\">",
"       Can breast cancer be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who are at high risk of getting breast cancer can sometimes take a medicine to help prevent the disease. If you have a strong family history of breast cancer, ask your doctor what you can do to prevent cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344375\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with breast cancer do very well after treatment. The important thing is to take your medicines as directed and to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for breast cancer involves making many choices. Besides choosing which surgery to have, you might have to choose which medicines to take and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there alternatives to this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H385344382\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=see_link\">",
"       Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=see_link\">",
"       Patient information: Breast reconstruction after mastectomy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"       Patient information: Common breast problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"       Patient information: Breast cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=see_link\">",
"       Patient information: Breast biopsy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=see_link\">",
"       Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"       Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"       Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=see_link\">",
"       Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=see_link\">",
"       Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=see_link\">",
"       Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=see_link\">",
"       Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=see_link\">",
"       Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"       Patient information: Breast cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"       Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"       Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/19/2357?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15365 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2357=[""].join("\n");
var outline_f2_19_2357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344326\">",
"      What is breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344333\">",
"      Is there a test for breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344340\">",
"      What is breast cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344347\">",
"      How is breast cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344354\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344361\">",
"      What happens if cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344368\">",
"      Can breast cancer be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344375\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H385344382\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15365\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/12/9412\">",
"      Lumpectomy and mastectomy to treat breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/53/25426?source=related_link\">",
"      Patient information: Adjuvant medical therapy for HER2-positive breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/10/44193?source=related_link\">",
"      Patient information: Breast biopsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/62/11236?source=related_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/8/8321?source=related_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=related_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/47/5875?source=related_link\">",
"      Patient information: Locally advanced and inflammatory breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/32/15876?source=related_link\">",
"      Patient information: Lymphedema after breast cancer surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=related_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/59/6066?source=related_link\">",
"      Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/44/27335?source=related_link\">",
"      Patient information: Surgical procedures for breast cancer &mdash; Mastectomy and breast conserving therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/11/27827?source=related_link\">",
"      Patient information: Treatment of metastatic breast cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_19_2358="Tuberculous pleurisy I PA";
var content_f2_19_2358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural thickening due to tuberculous pleurisy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tuberculous pleurisy with subacute diffuse pleural thickening. Frontal chest radiograph shows encasement of the right lung, which is poorly expanded. The right lateral costophrenic sulcus is blunted. The cardiomediastinal silhouette is shifted to the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2358=[""].join("\n");
var outline_f2_19_2358=null;
var title_f2_19_2359="Hymenolepis diminuta life cycle";
var content_f2_19_2359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Hymenolepis diminuta life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eggs of",
"    <em>",
"     Hymenolepis diminuta",
"    </em>",
"    are passed out in the feces of the infected definitive host (rodents, humans)",
"    <strong>",
"     (1)",
"    </strong>",
"    . The mature eggs are ingested by an intermediate host (various arthropod adults or larvae)",
"    <strong>",
"     (2)",
"    </strong>",
"    , and oncospheres are released from the eggs and penetrate the intestinal wall of the host",
"    <strong>",
"     (3)",
"    </strong>",
"    , which develop into cysticercoid larvae. Species from the genus",
"    <em>",
"     Tribolium",
"    </em>",
"    are common intermediate hosts for",
"    <em>",
"     H. diminuta",
"    </em>",
"    . The cysticercoid larvae persist through the arthropod's morphogenesis to adulthood.",
"    <em>",
"     H. diminuta",
"    </em>",
"    infection is acquired by the mammalian host after ingestion of an intermediate host carrying the cysticercoid larvae",
"    <strong>",
"     (4)",
"    </strong>",
"    . Humans can be accidentally infected through the ingestion of insects in precooked cereals, or other food items, and directly from the environment (eg, oral exploration of the environment by children). After ingestion, the tissue of the infected arthropod is digested releasing the cysticercoid larvae in the stomach and small intestine. Eversion of the scoleces",
"    <strong>",
"     (5)",
"    </strong>",
"    occurs shortly after the cysticercoid larvae are released. Using the four suckers on the scolex, the parasite attaches to the small intestine wall. Maturation of the parasites occurs within 20 days and the adult worms can reach an average of 30 cm in length",
"    <strong>",
"     (6)",
"    </strong>",
"    . Eggs are released in the small intestine from gravid proglottids",
"    <strong>",
"     (7)",
"    </strong>",
"    that disintegrate after breaking off from the adult worms. The eggs are expelled to the environment in the mammalian host's feces",
"    <strong>",
"     (1)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Hymenolepiasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/hymenolepiasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/hymenolepiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2359=[""].join("\n");
var outline_f2_19_2359=null;
var title_f2_19_2360="Deferasirox: Drug information";
var content_f2_19_2360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Deferasirox: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/16/41221?source=see_link\">",
"    see \"Deferasirox: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/8/41094?source=see_link\">",
"    see \"Deferasirox: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9935104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1987209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exjade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4432114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Exjade&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1987212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Chelating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1987289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Calculate dose to the nearest whole tablet size.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic iron overload due to blood transfusion:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should only be initiated with evidence of chronic iron overload (ie, transfusion of &ge;100 mL/kg of packed red blood cells [eg, &ge;20 units for a 40 kg individual] and serum ferritin consistently &gt;1000 mcg/L).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     Initial: 20 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     Dosing based on treatment goal and patient's individual transfusion rate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment goal: Maintenance of acceptable body iron levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial: 10 mg/kg once daily if transfused packed red blood cells (pRBCs) &lt;7 mL/kg/month (approximately &lt;2 units per month for an adult)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial: 20 mg/kg once daily if transfused pRBCs &ge;7 mL/kg/month (approximately &gt;2 units per month for an adult)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Treatment goal: Iron overload reduction:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial: 20 mg/kg once daily if transfused pRBCs &lt;14 mL/kg/month (approximately &lt;4 units per month for an adult)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial: 30 mg/kg once daily if transfused pRBCs &ge;14 mL/kg/month (approximately &gt;4 units per month for an adult)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: Adjust dose every 3-6 months based on serum ferritin trends; adjust by 5 or 10 mg/kg/day; titrate to individual response and treatment goals. Usual range: 20-30 mg/kg/day; doses up to 40 mg/kg/day may be considered for serum ferritin levels persistently &gt;2500 mcg/L (doses above 40 mg/kg/day are not recommended).",
"     <b>",
"      Note:",
"     </b>",
"     Consider interrupting therapy for serum ferritin &lt;500 mcg/L (risk of toxicity may be increased).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Chronic iron overload in non-transfusion-dependent thalassemia syndromes:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should only be initiated with evidence of chronic iron overload (hepatic iron concentration &ge;5 mg Fe/g dry weight and serum ferritin &gt;300 mcg/L).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Initial: 10 mg/kg once daily. Consider increasing to 20 mg/kg once daily after 4 weeks if baseline hepatic iron concentration is &gt;15 mg Fe/g dry weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Maintenance: Monitor serum ferritin monthly; if serum ferritin is &lt;300 mcg/L, interrupt therapy and obtain hepatic iron concentration. Monitor hepatic iron concentration every 6 months; interrupt therapy when hepatic iron concentration &lt;3 mg Fe/g dry weight. After 6 months of therapy, consider dose adjustment to 20 mg/kg/day if hepatic iron concentration &gt;7 mg Fe/g dry weight. Reduce dose to &le;10 mg/kg when hepatic iron concentration is 3-7 mg Fe/g dry weight. Doses above 20 mg/kg/day are not recommended. After interruption, resume treatment when hepatic iron concentration &gt;5 mg Fe/g dry weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Treatment should only be initiated with evidence of chronic iron overload (hepatic iron concentration &ge;5 mg Fe/g dry weight or serum ferritin consistently &gt;800 mcg/L).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: 10 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance: Do not exceed 10 mg/kg/day in patients whose hepatic iron concentration was not evaluated and if serum ferritin &le;2000 mcg/L. Monitor serum ferritin monthly; consider dose adjustment by 5 or 10 mg/kg/day every 3-6 months if hepatic iron concentration &ge;7 mg Fe/g dry weight or serum transferrin levels consistently &gt;2000 mcg/L.  Patients receiving &gt;10 mg/kg should have their dose reduced to &le;10 mg/kg when hepatic iron concentration &lt;7 mg Fe/g dry weight or serum ferritin &lt;2000 mcg/L.  Interrupt therapy when hepatic iron concentration &lt;3 mg Fe/g dry weight or serum ferritin &lt;300 mcg/L. Doses above 20 mg/kg/day are not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Dosage adjustment with concomitant bile acid sequestrants (eg,cholestyramine, colesevelam, colestipol) or potent UGT inducers (eg, rifampin, phenytoin, phenobarbital, ritonavir):",
"     </i>",
"     Avoid concomitant use; if coadministration necessary, consider increasing the initial dose of deferasirox dose by 50%; monitor serum ferritin and clinical response.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F1987288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/8/41094?source=see_link\">",
"      see \"Deferasirox: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Calculate dose to the nearest whole tablet size.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic iron overload due to blood transfusion:",
"     </b>",
"     Children &ge;2 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic iron overload in non-transfusion-dependent thalassemia syndromes:",
"     </b>",
"     Children &ge;10 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1987290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F1987291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     Creatinine clearance should be estimated using the Cockcroft-Gault formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Transfusional iron overload:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children &ge;2 years and Adolescents &lt;16 years: For increase in serum creatinine &gt;33% above the average baseline level and above the age-appropriate ULN: Reduce daily dose by 10 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Adolescents &ge;16 years and Adults: For increase in serum creatinine &ge;33% above the average baseline level for 2 consecutive weekly levels: Reduce daily dose by 10 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Non-transfusion-dependent thalassemia syndromes:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Children &ge;10 years and Adolescents &lt;16 years: For increase in serum creatinine &gt;33% above the average baseline level and above the age-appropriate ULN: Reduce daily dose by 5 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Adolescents &ge;16 years and Adults: For increase in serum creatinine &ge;33% above the average baseline level for 2 consecutive weekly levels: Interrupt therapy if the dose is 5 mg/kg; reduce dose by 50% if the dose is 10-20 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children &ge;2 years and Adolescents &lt;16 years: For increase in serum creatinine above the age-appropriate ULN for 2 consecutive levels, reduce daily dose by 10 mg/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Adolescents &ge;16 years and Adults: For increase in serum creatinine &gt;33% above the average pretreatment level for 2 consecutive weekly levels, reduce daily dose by 10 mg/kg.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F1987292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary; monitor closely for efficacy and for adverse reactions requiring dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate impairment (Child-Pugh class B): Initial: Reduce dose by 50%; monitor closely for efficacy and for adverse reactions requiring dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment (Child-Pugh class C): Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F1987293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bone marrow suppression: Interrupt treatment; may reinitiate once cause of cytopenia has been determined; use contraindicated if platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic toxicity (suspected erythema multiforme): Discontinue and evaluate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Discontinue treatment for suspected GI ulceration or hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hearing loss or visual disturbance: Consider dose reduction or treatment interruption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe rash: Interrupt treatment; may reintroduce at a lower dose (with future dose escalation) and short-term oral corticosteroids. Permanently discontinue treatment if erythema multiforme is suspected.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1987300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exjade&reg;: 125 mg, 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F1988061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F10982506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Deferasirox (Exjade&reg;) is only available through a restricted distribution program called EPASS&trade; Complete Care. Prescribers must enroll patients in this program in order to obtain the medication. For patient enrollment, contact 1-888-90-EPASS (1-888-903-7277).",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1987294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer tablets by making an oral suspension;",
"     <b>",
"      do not chew or swallow tablets whole.",
"     </b>",
"     Completely disperse tablets in water, orange juice, or apple juice (use 3.5 ounces for total doses &lt;1 g; 7 ounces for doses &ge;1 g); stir to form a fine suspension and drink entire contents. Rinse remaining residue with more fluid; drink. Administer at same time each day on an empty stomach, at least 30 minutes before food. Do not take simultaneously with aluminum-containing antacids.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1987214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or non-transfusion-dependent thalassemia syndromes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4432943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Deferasirox may be confused with deferiprone, deferoxamine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1987243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (19%), headache (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (dose related; 2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (dose related; 21% to 28%), nausea (dose related; 2% to 23%), vomiting (dose related; 10% to 21%), diarrhea (dose related; 5% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Serum creatinine increased (dose related; 2% to 38%), proteinuria (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (14%), nasopharyngitis (13%), pharyngolaryngeal pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Urticaria (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (1% to 8%), transaminitis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (7%), back pain (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Ear infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Respiratory tract infection (10%), bronchitis (9%), pharyngitis (8%), acute tonsillitis (6%), rhinitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, agranulocytosis, anaphylaxis, anemia (worsening), angioedema, anxiety, ascites, bilirubin increased, cataract, cholecystitis, cholelithiasis, constipation, cytopenias, dizziness, drug fever, duodenal ulcer, edema, erythema multiforme, esophagitis, Fanconi&rsquo;s syndrome, gastric ulcer, gastritis, gastrointestinal bleeding, gastrointestinal hemorrhage, glomerulonephritis, glucosuria, hearing loss (including high frequency), hematuria, Henoch-Sch&ouml;nlein purpura, hepatic dysfunction, hepatic encephalopathy, hepatic failure, hepatic transaminases increased, hepatitis, hyperactivity, hypersensitivity reaction, hypocalcemia, insomnia, intraocular pressure increased, jaundice, lens opacities, leukocytoclastic vasculitis, maculopathy, neutropenia, optic neuritis, pigment disorder, purpura, renal tubular necrosis, renal tubulopathy, retinal disorder, sleep disorder, thrombocytopenia, tubulointerstitial nephritis, visual disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1987218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to deferasirox or any component of the formulation; platelet counts &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; poor performance status; high-risk myelodysplastic syndromes; advanced malignancies; creatinine clearance &lt;40 mL/minute or serum creatinine &gt;2 x age-appropriate ULN",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1987219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Auditory disturbances: Decreased hearing and high frequency hearing loss have been reported (rare) with use; perform auditory testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Cytopenias (including agranulocytosis, neutropenia, thrombocytopenia, and worsening anemia) have been reported (some fatal); risk may be increased in patients with preexisting hematologic disorders; monitor blood counts regularly. Interrupt treatment in patients who develop cytopenias; may reinitiate once cause of cytopenia has been determined; use contraindicated if platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity: May cause skin rash (dose-related); mild-to-moderate rashes may resolve without treatment interruption; for severe rash, interrupt and consider restarting at a lower dose with dose escalation and oral steroids. Erythema multiforme has been reported; discontinue and evaluate if suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: Gastrointestinal (GI) hemorrhage (including fatalities) may occur; observed more frequently in elderly patients with advanced hematologic malignancies and/or low platelet counts; discontinue treatment for suspected GI hemorrhage or ulceration.",
"     </b>",
"     Other GI effects including irritation and ulceration have been reported. Use caution with concurrent medications that may increase risk of adverse GI effects (eg, NSAIDs, corticosteroids, anticoagulants, oral bisphosphonates). Monitor patients closely for signs/symptoms of GI ulceration/bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic failure:",
"     <b>",
"      [U.S. Boxed Warning]: Hepatic injury and failure (including fatalities) may  occur. Monitor transaminases and bilirubin at baseline, every 2 weeks for 1 month, then at least monthly thereafter.",
"     </b>",
"     Hepatitis and elevated transaminases have also been reported. Hepatotoxicity is more common in patients &gt;55 years of age and in patients with significant comorbidities (eg, cirrhosis, multiorgan failure). Reduce dose or temporarily interrupt treatment for severe or persistent increases in transaminases/bilirubin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions, including severe reactions (anaphylaxis and angioedema) have been reported; onset is usually within the first month of treatment. Discontinue if severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disturbances: Lens opacities, cataracts, intraocular pressure elevation, and retinal disorders have been reported (rare) with use; perform ophthalmic testing prior to initiation and regularly (every 12 months) during use; if abnormalities develop, monitor more closely and consider dose reduction or treatment interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal failure:",
"     <b>",
"      [U.S. Boxed Warning]: Acute renal failure (including fatalities and cases requiring dialysis) may occur; observed more frequently in patients with comorbid conditions and advanced hematologic malignancies. Obtain serum creatinine and calculate creatinine clearance in duplicate at baseline prior to initiation, and monitor at least monthly thereafter; in patients with underlying renal dysfunction or at risk for acute renal failure, monitor creatinine weekly during the first month then at least monthly thereafter. Dose reduction, interruption, or discontinuation should be considered for serum creatinine elevations.",
"     </b>",
"     Monitor serum creatinine and/or creatinine clearance more frequently if creatinine levels are increasing. May cause proteinuria; monitor monthly although the clinical significance of proteinuria is unknown. Renal tubular damage, including Fanconi&rsquo;s syndrome, has also been reported, primarily in pediatric/adolescent patients with &beta;-thalassemia and serum ferritin levels &lt;1500 mcg/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other iron chelation drugs: Not approved for use in combination with other iron chelation therapies; safety of combinations has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; UGT inducers or bile acid sequestrants: Potent UGT inducers (eg, rifampin) or bile acid sequestrants (eg, cholestyramine) may decrease the efficacy of deferasirox; avoid concomitant use. If coadministration necessary, dosage modifications may be needed; monitor serum ferritin and clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid use in patients with severe (Child-Pugh class C) hepatic impairment; a dose reduction is required in patients with moderate (Child-Pugh class B) hepatic impairment.",
"     </b>",
"     Monitor patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment closely for efficacy and for adverse reactions requiring dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution (has not been studied).  Dosage modification or treatment discontinuation may be required; use is contraindicated in patients with a creatinine clearance &lt;40 mL/minute or serum creatinine &gt;2 x age-appropriate ULN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution due to the higher incidence of toxicity (eg, hepatotoxicity) and fatal events during use; monitor elderly patients closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: May contain lactose; Canadian product labeling recommends avoiding use in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For transfusion-related iron overload, treatment should be initiated with evidence of chronic iron overload (ie, transfusion of &ge;100 mL/kg of packed RBCs [eg, &ge;20 units for a 40 kg individual] and serum ferritin consistently &gt;1000 mcg/L). For non-transfusion-dependent iron overload, initiate with liver iron concentration &ge;5 mg Fe/g dry liver weight, and serum ferritin &gt;300 mcg/L. Prior to use, consider risk versus anticipated benefit with respect to individual patient&rsquo;s life expectancy, prognosis, and comorbidities. An improvement in survival or disease-related symptoms due to the therapy has not been established in clinical trials. Postmarketing experience indicates serious reactions, including fatalities, has occurred with deferasirox use, particularly when used in older patients with comorbidities or advanced disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Overchelation: Overchelation of iron may increase development of toxicity; consider temporary interruption of treatment in transfusional iron overload when serum ferritin &lt;500 mcg/L; in non-transfusion-dependent thalassemia when serum ferritin &lt;300 mcg/L or hepatic iron concentration &lt;3 mg Fe/g dry weight.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9935524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of UGT1A1;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2C8 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1987249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: May diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: Deferasirox may increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: Deferasirox may increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: Deferasirox may decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Deferasirox may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Deferasirox. Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline: Deferasirox may increase the serum concentration of Theophylline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13842282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Bioavailability is increased variably when taken with food. Management: Take on an empty stomach at the same time each day at least 30 minutes before food. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1987215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1987216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F1987217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13315456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if deferasirox is excreted in breast milk. The decision to discontinue deferasirox or to discontinue breast-feeding during therapy should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1987253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability increased variably when taken with food; take on empty stomach 30 minutes before a meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet,Dispersible",
"     </b>",
"     (Exjade Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (30): $768.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (30): $1536.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (30): $3073.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1987296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum ferritin (baseline, monthly thereafter), iron levels (baseline), CBC with differential, serum creatinine and creatinine clearance (2 baseline assessments then monthly thereafter; in patients who are at increased risk of complications [eg, pre-existing renal conditions, elderly, comorbid conditions, or receiving other potentially nephrotoxic medications]: weekly for the first month then at least monthly thereafter); liver iron concentration (non-transfusion-dependent thalassemia; baseline, every 6 months); urine protein (monthly); monitor serum creatinine and/or creatinine clearance more frequently if creatinine levels are increasing;  serum transaminases (ALT/AST) and bilirubin (baseline, every 2 weeks for the first month, then monthly); baseline and annual auditory and ophthalmic function (including slit lamp examinations and dilated fundoscopy); performance status (in patients with hematologic malignancies); signs and symptoms of GI ulcers or hemorrhage; cumulative number of RBC units received",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling also recommends monitoring growth and body weight every 12 months in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Exjade (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1987256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively binds iron, forming a complex which is excreted primarily through the feces.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1987259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Adults: 14.4 &plusmn; 2.7L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~99% to serum albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via glucuronidation by UGT1A1(primarily) and UGT1A3; minor oxidation by CYP450; undergoes enterohepatic recirculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 8-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: ~1.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (84%); urine (8%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bacon BR, Adams PC, Kowdley KV, et al, &ldquo;Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Disease,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(1):328-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/21452290/pubmed\" id=\"21452290\" target=\"_blank\">",
"        21452290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cappellini MD, Cohen A, Piga A, et al, &ldquo;A Phase 3 Study of Deferasirox (ICL670), a Once-Daily Oral Iron Chelator, in Patients With Beta-Thalassemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(9):3455-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/16352812/pubmed\" id=\"16352812\" target=\"_blank\">",
"        16352812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cappellini MD, &ldquo;Long-Term Efficacy and Safety of Deferasirox,&rdquo;",
"      <i>",
"       Blood Rev",
"      </i>",
"      , 2008, 22(Suppl 2):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/19059055/pubmed\" id=\"19059055\" target=\"_blank\">",
"        19059055",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen AR, Glimm E, and Porter JB, &ldquo;Effect of Transfusional Iron Intake on Response to Chelation Therapy in &beta;-Thalassemia Major,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(2):583-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/17951527/pubmed\" id=\"17951527\" target=\"_blank\">",
"        17951527",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Galanello R, Piga A, Alberti D, et al, \"Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients With Transfusion-Dependent Iron Overload Due to Beta-Thalassemia,\"",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2003, 43(6):565-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/12817519/pubmed\" id=\"12817519\" target=\"_blank\">",
"        12817519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      List AF, Baer MR, Steensma DP, et al, \"Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients With Myelodysplastic Syndrome,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(17):2134-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/22547607/pubmed\" id=\"22547607\" target=\"_blank\">",
"        22547607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nisbet-Brown E, Oliveri NF, Giardina PJ, et al, \"Effectiveness and Safety of ICL670 in Iron-Loaded Patients With Thalassaemia: A Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 361(9369):1597-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/12747879/pubmed\" id=\"12747879\" target=\"_blank\">",
"        12747879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pennell DJ, Porter JB, Cappellini MD, et al, &ldquo;Efficacy of Deferasirox in Reducing and Preventing Cardiac Iron Overload in Beta-Thalassemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 115(12):2364-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/19996412/pubmed\" id=\"19996412\" target=\"_blank\">",
"        19996412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porter JB, &ldquo;Optimizing Iron Chelation Strategies In Beta-Thalassaemia Major,&rdquo;",
"      <i>",
"       Blood Rev",
"      </i>",
"      , 2009, 23(Suppl 1):3-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/20116637/pubmed\" id=\"20116637\" target=\"_blank\">",
"        20116637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porter J, Galanello R, Saglio G, et al, &ldquo;Relative Response of Patients With Myelodysplastic Syndromes and Other Transfusion-Dependent Anaemias to Deferasirox (ICL670): A 1-Yr Prospective Study,&rdquo;",
"      <i>",
"       Eur J Haematol",
"      </i>",
"      , 2008, 80(2):168-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/18028431/pubmed\" id=\"18028431\" target=\"_blank\">",
"        18028431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raphael JL, Bernhardt MB, Mahoney DH, et al, &ldquo;Oral Iron Chelation and the Treatment of Iron Overload in a Pediatric Hematology Center,&rdquo;",
"      <i>",
"       Pediatr Blood Cancer",
"      </i>",
"      , 2009, 52(5):616-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/19148949/pubmed\" id=\"19148949\" target=\"_blank\">",
"        19148949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taher AT, Porter J, Viprakasit V, et al, &ldquo;Deferasirox Reduces Iron Overload Significantly in Nontransfusion-Dependent Thalassemia: 1-Year Results From a Prospective, Randomized, Double-Blind, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 120(5):970-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/22589472/pubmed\" id=\"22589472\" target=\"_blank\">",
"        22589472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vichinsky E, Onyekwere O, Porter J, et al, &ldquo;A Randomised Comparison of Deferasirox Versus Deferoxamine for the Treatment of Transfusional Iron Overload in Sickle Cell Disease,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2007, 136(3):501-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/17233848/pubmed\" id=\"17233848\" target=\"_blank\">",
"        17233848",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf B, McPhedran P, and Brewster UC, &ldquo;Hypocalcemia in a Dialysis Patient Treated With Deferasirox for Iron Overload,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2008, 52(3):587-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/19/2360/abstract-text/18534729/pubmed\" id=\"18534729\" target=\"_blank\">",
"        18534729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8794 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-F7DA7CD4CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2360=[""].join("\n");
var outline_f2_19_2360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9935104\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987209\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4432114\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987212\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987289\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987288\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987290\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987291\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987292\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987293\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987300\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1988061\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10982506\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987294\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987214\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4432943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987243\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987218\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987219\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9935524\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987249\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842282\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987215\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987216\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987217\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315456\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987253\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322889\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987296\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539963\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987256\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987259\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8794\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8794|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/16/41221?source=related_link\">",
"      Deferasirox: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/8/41094?source=related_link\">",
"      Deferasirox: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_19_2361="Gastric polyps";
var content_f2_19_2361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gastric polyps",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/19/2361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2361/contributors\">",
"     Varocha Mahachai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2361/contributors\">",
"     David Y Graham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2361/contributors\">",
"     Robert D Odze, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/19/2361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2361/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/19/2361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2361/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/19/2361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric polyps are typically found incidentally when upper gastrointestinal endoscopy is performed for an unrelated indication; only rarely do they cause symptoms or other clinical signs. Nevertheless, their discovery can be important since some types of polyps have malignant potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric polyps are found in approximately 6 percent of upper gastrointestinal endoscopic procedures in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/1\">",
"     1",
"    </a>",
"    ]. In one large series, polyps occurred in men and women equally, were multiple in more than 25 percent, and were found in patients between the ages of 22 to 87 years, with two-thirds occurring in patients over 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of gastric polyps and the types of polyps most commonly identified vary widely depending upon the population being studied, with lower rates of polyp detection being reported outside of the United States. Hyperplastic polyps and adenomas are relatively more frequent than fundic gland polyps in regions where Helicobacter pylori (H. pylori) infection is common [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In an illustrative series from Greece, polyps were detected in 157 of 12,974 patients undergoing upper endoscopy (1.2 percent). The majority of polyps (75 percent) were hyperplastic, while noninvasive intraepithelial neoplasia, also called adenomas (",
"    <a class=\"graphic graphic_picture graphicRef64653 \" href=\"UTD.htm?9/53/10064\">",
"     picture 1",
"    </a>",
"    ), was found in approximately 7 percent of the patients with polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/2\">",
"     2",
"    </a>",
"    ]. Similarly, in a study from Brazil, a gastric polyp was found in 0.6 percent of 26,000 endoscopies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/4\">",
"     4",
"    </a>",
"    ]. About 70 percent of gastric polyps were hyperplastic (",
"    <a class=\"graphic graphic_picture graphicRef80276 \" href=\"UTD.htm?13/35/13887\">",
"     picture 2",
"    </a>",
"    ), while 12 percent were noninvasive intramucosal neoplasia (adenomas), and 16 percent were fundic gland polyps. By contrast, in Western countries, where H. pylori infection is less frequent and proton pump inhibitor use is common, the most commonly encountered polyps are fundic gland polyps (",
"    <a class=\"graphic graphic_picture graphicRef78092 graphicRef58144 \" href=\"UTD.htm?4/29/4565\">",
"     picture 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some polyps are associated with familial cancer syndromes. For example, fundic gland polyps are seen in patients with familial adenomatous polyposis and hamartomatous polyps are seen in patients with Peutz-Jeghers syndrome. These associations are helping to uncover how specific genetic mutations are responsible for polyp formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, once a polyp is observed, it is removed or biopsied and its pathology identified. Prognosis and management are specific to the underlying pathology. However, pathology is generally not known at the time of the initial endoscopy and some general management issues are commonly applied to all patients with gastric polyps.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyp histology &ndash; Because of the risk for cancer, all gastric polyps should be examined microscopically for histologic characterization [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/5-9\">",
"       5-9",
"      </a>",
"      ]. Adequate biopsy samples should be obtained prior to polypectomy, because polyps occasionally cannot be retrieved after they are removed. Forceps biopsy alone cannot exclude foci of high-grade dysplasia or even early gastric cancer in large (ie, &gt;1 cm) polyps. As a result, polypectomy is generally indicated for all neoplastic polyps and other polyps &ge;1 cm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/7\">",
"       7",
"      </a>",
"      ]. Endoscopic mucosal resection provides an accurate histological assessment of sessile lesions and also achieves their complete removal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"       \"Overview of endoscopic resection of gastrointestinal tumors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition, all patients with hyperplastic gastric polyps should be tested for H. pylori and, if positive, treated with eradication therapy. Because the pathology is often not known at the time of initial endoscopy, we also biopsy the normal appearing mucosa of patients with gastric polyps for H. pylori. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hyperplastic polyps'",
"      </a>",
"      below.) for the discussion on management and (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"       \"Treatment regimens for Helicobacter pylori\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gastric mucosa histology &ndash; Because hyperplastic polyps and adenomatous polyps are often associated with atrophic gastritis, the normal appearing antral and corpus mucosa should be sampled to assess the stage and type of gastritis and, thus, cancer risk. An international group of pathologists and gastroenterologists have introduced a gastric mucosal staging system designed to provide an estimate of the risk of developing gastric cancer based on the degree of antral and corpus atrophy, the operative link on gastritis assessment (OLGA) staging system [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. The risk is scored 0 to 4. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link\">",
"       \"Classification and diagnosis of gastritis and gastropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link\">",
"       \"Metaplastic (chronic) atrophic gastritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link\">",
"       \"Risk factors for gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surveillance &ndash; Patients in whom polyps are not removed require follow-up endoscopy to document regression. There are limited data regarding surveillance in patients with gastric polyps. Recommendations have been issued by the American Society for Gastrointestinal Endoscopy (ASGE) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gastric adenomas'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      In patients at higher risk for gastric cancer (eg, extensive atrophy such as OLGA stage 3 or 4, patients with adenomatous polyps), we suggest surveillance endoscopy at regular intervals (one to three years). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link\">",
"       \"Risk factors for gastric cancer\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H14\">",
"       'Gastric adenomas'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      In patients without these risk factors and with minimal risk (eg, OLGA stage 1 or 2), we generally perform at least one follow-up endoscopy to confirm that H. pylori has been eradicated and that there are no new or residual polyps. Patients with fundic gland polyps that are not associated with familial adenomatous polyposis (FAP) or attenuated FAP generally do not require further surveillance.",
"     </li>",
"     <li>",
"      Multiple polyps &ndash; Some patients have multiple polyps, which makes it difficult and impractical to remove them all. The ASGE (",
"      <a class=\"graphic graphic_table graphicRef65402 \" href=\"UTD.htm?43/44/44747\">",
"       table 1",
"      </a>",
"      ) recommends that the largest polyp should be excised with representative biopsies obtained from the remaining polyps [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/12\">",
"       12",
"      </a>",
"      ]. Further management should be based upon the histology of the polyp.",
"     </li>",
"     <li>",
"      Relationship to colonic polyps &ndash; The observation that gastric polyps occur in patients with FAP raised the question of whether finding a gastric polyp, particularly a fundic gland polyp, might be a marker for colon neoplasia in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. A retrospective study found that patients with nonmalignant mucosal gastric polyps had a significantly greater incidence of colonic polyps (OR 3.19), colonic neoplasms (OR 3.58), and colon cancer (OR 4.5) than controls [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/14\">",
"       14",
"      </a>",
"      ]. However, other studies have not confirmed such an association [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgery &ndash; Surgery can be avoided if a removed and retrieved polyp shows early carcinoma that is moderately or well differentiated and confined to the mucosa, and there is no non-polyp carcinoma elsewhere [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/16\">",
"       16",
"      </a>",
"      ]. More advanced or less well differentiated polyps may require surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"       \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HYPERPLASTIC POLYPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperplastic polyps account for the great majority (75 percent) of gastric polyps in geographic areas where H. pylori is common. They are small, dome-shaped, or stalked polyps (average size 1.0 cm, range 0.1 to 12 cm) that may be single or multiple in number. They primarily occur in the antrum, but may develop in the fundus or cardia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopically, they are composed of elongated, dilated,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cystic, architecturally distorted, foveolar epithelium within an edematous, congested, and often actively and chronically inflamed lamina propria (",
"    <a class=\"graphic graphic_picture graphicRef72171 \" href=\"UTD.htm?41/45/42713\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Variable features include epithelial regenerative changes, dystrophic goblet cells, intestinal metaplasia, pyloric metaplasia (in corpus and fundic lesions), surface erosion, and ulceration.",
"   </p>",
"   <p>",
"    The pathogenesis of hyperplastic polyps is related to unchecked, hyper-regenerative epithelium in response to an underlying chronic inflammatory stimulus. Over time, the polyps may regress, remain stable, or increase in size. As noted above, they often regress following H. pylori eradication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperplastic polyps are often multiple (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79352 \" href=\"UTD.htm?17/20/17743\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/2,19\">",
"     2,19",
"    </a>",
"    ], and are generally observed in the setting of chronic inflammatory conditions (such as chronic atrophic gastritis), pernicious anemia, chronic antral gastritis, adjacent to ulcers and erosions, and especially at sites of gastroenterostomies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/20\">",
"     20",
"    </a>",
"    ]. Men and women are equally affected and the polyps typically appear in mid to late adult life.",
"   </p>",
"   <p>",
"    Polyps that cause symptoms are most likely to present with gastrointestinal bleeding (usually occult but occasionally overt) or rarely obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The latter occurs with pedunculated polyps in the antrum that prolapse into or through the pylorus (",
"    <a class=\"graphic graphic_picture graphicRef50167 \" href=\"UTD.htm?6/38/6754\">",
"     picture 5",
"    </a>",
"    ). Symptoms are usually intermittent as the polyp moves about on its stalk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Malignant potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of malignant change within a hyperplastic polyps ranges from 0.5 to 7.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. Malignancy develops through a",
"    <span class=\"nowrap\">",
"     dysplasia/carcinoma",
"    </span>",
"    sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/1,25,28\">",
"     1,25,28",
"    </a>",
"    ]. The risk of malignancy in hyperplastic polyps is greater in polyps more than 2 cm and pedunculated in shape, but invasive cancer (into the muscularis propria or serosa) is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/25\">",
"     25",
"    </a>",
"    ]. Resection of the polyp does not change the cancer risk related to the underlying atrophic gastritis. Therefore, it is recommended to stage the gastritis in terms of cancer risk separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link\">",
"     \"Risk factors for gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment in most instances is simple excision. Large (&gt;2 cm) hyperplastic polyps are at increased risk for malignant transformation and should be resected completely [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because hyperplastic polyps are associated with atrophic gastritis and H. pylori infection, the normal appearing antral and corpus mucosal should be sampled to assess the stage of gastritis and, thus, cancer risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link\">",
"     \"Metaplastic (chronic) atrophic gastritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link\">",
"     \"Risk factors for gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .) Follow-up should be based on the cancer risk such as that based on the OLGA stage.",
"   </p>",
"   <p>",
"    All patients with gastric polyps should be tested for H. pylori and, if positive, treated with eradication therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .) Treatment of H. pylori has been associated with regression of polyps in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In a randomized treatment study of 35 patients with hyperplastic gastric polyps at least 3 mm in diameter and evidence of H. pylori infection, complete regression of polyps at 12 to 15 months was observed more often in patients in whom H. pylori was cured (80 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/30\">",
"     30",
"    </a>",
"    ]. We generally perform at least one follow-up endoscopy to confirm H. pylori eradication and absence of residual polyps.",
"   </p>",
"   <p>",
"    A subtotal gastrectomy may be considered when dysplasia or carcinoma is present beyond the confines of the polyp. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .) At a minimum, endoscopic mucosal resection and surveillance with extensive sampling of the remainder of the stomach to rule out multifocal dysplasia at one- to three-year intervals is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FUNDIC GLAND POLYPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundic gland polyps are typically small (0.1 to 0.8 cm), hyperemic, sessile, flat, nodular lesions that have a smooth surface contour (",
"    <a class=\"graphic graphic_picture graphicRef78092 graphicRef58144 \" href=\"UTD.htm?4/29/4565\">",
"     picture 3A-B",
"    </a>",
"    ). They occur exclusively in the gastric corpus. However, they can sometimes be large and we recommend removal of polyps greater than 1 cm in size.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundic gland polyps are composed of normal gastric corpus-type epithelium, arranged in a disorderly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microcystic configuration (",
"    <a class=\"graphic graphic_picture graphicRef66607 \" href=\"UTD.htm?21/17/21782\">",
"     picture 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/4,7,31\">",
"     4,7,31",
"    </a>",
"    ]. Microcysts are characteristic, and may be lined by any of the normal cell types found in the gastric corpus. The glandular compartment typically reveals distorted architecture with irregular gland buds, tortuous glands, or irregular stellate glandular configurations. Inflammation is usually minimal. Mild hyperplasia of the muscularis mucosa may occur in a pericystic configuration. These lesions probably arise from proliferation and differentiation of aberrantly located proliferative cells in the stem cell compartment of the corpus epithelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundic gland polyps are usually asymptomatic and discovered incidentally at endoscopy. They may rarely reach a size large enough to cause obstruction and symptoms such as abdominal pain and vomiting. Fundic gland polyps may occur sporadically or in association with polyposis syndromes, familial adenomatous polyposis (FAP) or attenuated FAP, MUTYH associated polyposis (MAP), and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link&amp;anchor=H18#H18\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\", section on 'MUTYH associated polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sporadic polyps occur in females more often than males, usually in middle age. Up to 40 percent of patients have multiple polyps.",
"   </p>",
"   <p>",
"    Long-term therapy with proton pump inhibitors (PPIs) has been shown to be associated with fundic gland polyps (",
"    <a class=\"graphic graphic_picture graphicRef78092 graphicRef58144 \" href=\"UTD.htm?4/29/4565\">",
"     picture 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77794 \" href=\"UTD.htm?38/58/39843\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/3,31,35-38\">",
"     3,31,35-38",
"    </a>",
"    ]. A study of 599 patients undergoing endoscopy found that long-term (&ge;5 years) PPI use was associated with a fourfold increased risk of fundic gland polyps, while short-term (&lt;1 year) PPI therapy was not associated with increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/3\">",
"     3",
"    </a>",
"    ]. Regression of fundic gland polyps following withdrawal of PPIs provides further support for this association.",
"   </p>",
"   <p>",
"    H. pylori infection appears to protect against the development of fundic gland polyps. The incidence of H. pylori infection is very low in patients with fundic gland polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/1\">",
"     1",
"    </a>",
"    ]. Regression of fundic gland polyps has also been reported following an H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/35,39\">",
"     35,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fundic gland polyps occur in 20 to 100 percent of patients with FAP and 11 percent of patients with MAP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/34,40\">",
"     34,40",
"    </a>",
"    ]. Compared with sporadic fundic gland polyps in FAP, men and women are affected equally, polyps develop at an earlier age (mean 40 years) than sporadic fundic gland polyps, and are multiple in more than 90 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Malignant potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundic gland polyps have virtually no malignant potential when associated with PPI use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/3,36,38\">",
"     3,36,38",
"    </a>",
"    ] or when occurring sporadically [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, the presence of fundic gland polyps in patients taking chronic PPIs who do not have a family history of polyps is not an indication for colonoscopy.",
"   </p>",
"   <p>",
"    In contrast, fundic gland polyps associated with polyposis syndromes have been associated with progression to malignancy. The lifetime risk of gastric cancer in patients with FAP is 1 percent. The presence of multiple fundic gland polyps in young patients or those without PPI use should raise the possibility of an underlying polyposis syndrome.",
"   </p>",
"   <p>",
"    Dysplasia developing in fundic gland polyps associated with FAP and attenuated FAP syndromes is not uncommon. Up to 40 percent of fundic gland polyps in patients with FAP show dysplasia, which is typically low grade [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Somatic APC gene mutations have been detected in over 70 percent of syndromic fundic gland polyps without dysplasia, but in less than 10 percent of sporadic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/45\">",
"     45",
"    </a>",
"    ]. The prevalence and significance of dysplasia (typically located in the surface-foveolar epithelium overlying the polyp) in large clinical series of syndromic fundic gland polyps has yet to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundic gland polyps are frequently multiple and biopsy sampling of one or several is sufficient. However, fundic gland polyps &ge;1 cm in diameter should probably be removed and, if multiple, withdrawal of the PPI should be considered.",
"   </p>",
"   <p>",
"    As progression to gastric cancer is rare, regular surveillance by upper endoscopy is not routinely recommended for sporadic fundic gland polyps without dysplasia. However, surveillance with upper endoscopy is recommended for individuals with FAP and MAP (for both gastric and duodenal polyps) and in individuals with sporadic fundic gland polyps with dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/42,46-48\">",
"     42,46-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GASTRIC ADENOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric adenomas are also called adenomatous polyps. These account for 6 to 10 percent of gastric polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Most are found in the antrum, but some occur in the corpus and cardia. Adenomas may be flat or polypoid, and range in size from a few millimeters to several centimeters (",
"    <a class=\"graphic graphic_picture graphicRef64653 \" href=\"UTD.htm?9/53/10064\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopically, these lesions are similar to typical colonic adenomas (",
"    <a class=\"graphic graphic_picture graphicRef74367 \" href=\"UTD.htm?39/47/40694\">",
"     picture 8",
"    </a>",
"    ). They may be tubular, tubulovillous, or villous (papillary), are sessile or stalked, and occasionally reach large sizes (up to 15 cm). They may have an intestinal or gastric phenotype or some may be mixed.",
"   </p>",
"   <p>",
"    Gastric adenomas are neoplastic and are formed of dysplastic columnar cells with striated borders, often intermixed with dysplastic goblet cells, Paneth cells, parietal cells, or endocrine cells. The dysplastic cells show elongated, pencil-shaped nuclei with hyperchromasia, clumped chromatin, and pseudostratification. These lesions are often associated with underlying chronic gastritis with intestinal metaplasia. Some show a gastric phenotype composed of dysplastic mucinous foveolar cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric adenomas typically occur in a background of chronic gastritis. They occur in males and females equally, predominantly in middle and older age subjects. The incidence may be slightly increased in patients with familial adenomatous polyposis (FAP). Similar to other types of polyps, polyps that cause symptoms are most likely to present with gastrointestinal bleeding (usually occult but occasionally overt) or rarely obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Malignant potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with adenomatous colonic polyps, adenomatous polyps of the stomach have been defined by the World Health Organization as noninvasive intramucosal neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. This name reflects the concept that gastric epithelial dysplasia is actually not a \"benign\" lesion but rather is a noninvasive intraepithelial neoplasia and a precursor lesion of gastric adenocarcinoma. The pathogenesis of dysplasia is the same as that of gastric adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric adenomas typically form in atrophic gastric mucosa, and high-grade dysplasia has been identified in close proximity to a high proportion (40 to 100 percent) of early gastric cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/52\">",
"     52",
"    </a>",
"    ]. It has been estimated that 8 to 59 percent of cases of dysplasia are associated with synchronous gastric carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-grade dysplasia is a direct precursor to invasive gastric cancer and",
"    <span class=\"nowrap\">",
"     cytologically/biologically",
"    </span>",
"    is considered a malignancy by Japanese pathologists [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/54\">",
"     54",
"    </a>",
"    ]. Western pathologists require demonstration of penetration of the muscularis mucosa to declare a malignancy. In one follow-up study of 16 cases of high-grade dysplasia, invasive carcinoma was diagnosed in 11 (68 percent) during a mean follow-up of 30 months (range 13 to 72 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/55\">",
"     55",
"    </a>",
"    ]. In a nationwide cohort study in the Netherlands, 25 percent of patients with high-grade dysplasia were diagnosed with gastric carcinoma within one year of follow-up after initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with low-grade dysplasia have a lower but still substantial risk of progression to cancer, estimated at 0 to 9 percent within 15 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of invasive carcinoma in an adenoma correlates with increasing size, villous contour, and higher grades of dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/25,58\">",
"     25,58",
"    </a>",
"    ]. The risk of malignancy is lower in flat adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cancer risk in dysplasia is sufficiently high to justify removing all gastric adenomas (ie, they are intraepithelial neoplastic lesions). This can typically be accomplished endoscopically but on occasion surgery may be required for lesions that contain invasive carcinoma or cases in which multiple adenomas are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the association of gastric dysplasia with synchronous gastric carcinomas, the remainder of the stomach must be examined carefully [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Also, because adenomatous polyps are associated with atrophic gastritis, the normal appearing antral and corpus mucosa should be sampled to assess the stage of gastritis and, thus, cancer risk. All patients should be tested for active H. pylori infection and, if present, the infection should be treated.",
"   </p>",
"   <p>",
"    Patients with adenomatous polyps are at high risk for gastric cancer should have regular endoscopic surveillance. The ASGE recommends surveillance one year after removing adenomatous gastric polyps to assess recurrence at the prior excision site, new or previously missed polyps, confirmation of H. pylori eradication,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supervening early carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/12\">",
"     12",
"    </a>",
"    ]. In countries with a high risk of gastric cancer such as Japan or Korea, surveillance is continued indefinitely.",
"   </p>",
"   <p>",
"    Despite the association of FAP with fundic gland polyps and dysplasia, there is controversy as to whether patients with FAP are at significantly increased risk for gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/46,60\">",
"     46,60",
"    </a>",
"    ]. One registry, for example, found no increase in the risk of gastric cancer but marked increases in the risk of duodenal and periampullary adenocarcinomas (relative risk 331 and 124, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/46\">",
"     46",
"    </a>",
"    ]. Regular surveillance by upper endoscopy is warranted to look at the duodenum, and the stomach can be conveniently evaluated during the same procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/46,48\">",
"     46,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     GASTRIC CARCINOID TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric carcinoid tumors may grow as a polypoid lesion and, depending upon the etiology, may occur in the antrum, but most commonly they are present in the corpus. They are usually sessile, broad-based nodules, with a smooth surface contour (",
"    <a class=\"graphic graphic_picture graphicRef77477 \" href=\"UTD.htm?19/28/19906\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four histologic architectural patterns in gastric carcinoids, but it is common to find a mixture of these patterns in any particular lesion: solid or insular; trabecular; glandular; and undifferentiated, or diffuse (",
"    <a class=\"graphic graphic_picture graphicRef63323 \" href=\"UTD.htm?13/62/14311\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Most gastric carcinoid tumors have a very prominent, solid nest or insular pattern, particularly those that arise from enterochromaffin-like cells. In addition, gastric carcinoids are sometimes classified as well differentiated or poorly differentiated, depending upon the prominence of the growth pattern.",
"   </p>",
"   <p>",
"    Cytologically, carcinoid tumors show a homogeneous, regular population of round to oval-shaped cells with round to oval nuclei containing a characteristic stippled or speckled chromatin pattern. Carcinoids that develop in association with the Zollinger-Ellison syndrome or pernicious anemia may be associated with hyperplastic or dysplastic endocrine growths in the adjacent gastric mucosa.",
"   </p>",
"   <p>",
"    The pathologic diagnosis is usually established by recognizing the characteristic cytologic and architectural pattern of the cells, combined with immunohistochemical reactivity for chromogranin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    synaptophysin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/64\">",
"     64",
"    </a>",
"    ]. Electron microscopy may be useful to confirm the presence of neurosecretory granules in the cytoplasm of tumor cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric carcinoids are grouped into three categories, types 1, 2, and 3, and vary with regard to their association with atrophic gastritis (type 1), gastrinomas or multiple endocrine neoplasia (type 2), or neither (type 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric carcinoids may, as with other gastric polyps, be asymptomatic or present with peptic ulcer disease, with abdominal pain or bleeding, or, primarily with type 3 lesions, symptoms of the carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Malignant potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 tumors account for 15 to 20 percent of gastric carcinoids, and are the most aggressive; local or hepatic metastases are present in up to 65 percent of patients who come to resection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/66,68\">",
"     66,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management depends on the type of gastric carcinoid (type 1, 2, or 3). For type 1 and 2 gastric carcinoids smaller than 1 cm, endoscopic resection is the treatment of choice. Sporadic (type 3) gastric carcinoids are treated by partial or total gastrectomy with local lymph node resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    .) Type 1 carcinoids typically arise in response to prolonged marked hypergastrinemia associated with corpus atrophy (ie, with pernicious anemia). Antrectomy will remove the gastrin stimulus and is often the treatment of choice for those with multiple fundic carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2361/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most gastric polyps are asymptomatic and discovered incidentally.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence and significance of gastric polyps varies between and among populations. The falling incidence of Helicobacter pylori (H. pylori) infections has reduced the incidence of hyperplastic polyps and adenomatous polyps. By contrast, increasing use of proton pump inhibitors (PPIs) chronically has been associated with an increasing incidence of fundic gland polyps. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once observed, we recommend that polyps be biopsied and removed if possible (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If multiple, a representative sample of polyps should be biopsied and the pathology identified; those greater than 1 cm should be removed, if possible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because adenomatous and hyperplastic polyps are associated with atrophic gastritis and H. pylori infection, the normal appearing antral and corpus mucosal should be sampled to assess the stage of gastritis and, thus, cancer risk, and the patient should be tested for H. pylori infection. We suggest H. pylori eradication therapy in those who test positive. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gastric epithelial polyps can be classified as fundic gland, hyperplastic, adenomas, or carcinoid tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fundic gland polyps may occur sporadically, in association with polyposis syndromes, or in response to chronic PPI therapy. They have very low to no malignant potential when associated with PPI use or occurring sporadically. Fundic gland polyps associated with polyposis syndromes familial adenomatous polyposis (FAP) and MUTYH associated polyposis (MAP) have been associated with progression to malignancy. Fundic gland polyps &ge;1 cm in diameter should be removed and, if multiple, withdrawal of the PPI should be considered. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fundic gland polyps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperplastic polyps account for the great majority of gastric polyps and are typically seen in association with H. pylori-related atrophic gastritis, pernicious anemia, and adjacent to ulcers and erosions. They are generally benign, but have some malignant potential. Treatment of H. pylori has been associated with regression of polyps in some patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hyperplastic polyps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric adenomas typically form in atrophic gastric mucosa, and are considered noninvasive intraepithelial neoplasia and a precursor lesion of gastric adenocarcinoma. Because of the high cancer risk in adenomas, we recommend removal of all gastric adenomas endoscopically or surgically if necessary (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Gastric adenomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric carcinoid malignant tumors may grow as a polypoid lesion and account for 15 to 20 percent of gastric carcinoids, with the presence of local or hepatic metastases in up to 65 percent of patients who come to resection. Management depends on the type of gastric carcinoid (type 1, 2, or 3). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gastric carcinoid tumors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"       \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/1\">",
"      Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009; 104:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/2\">",
"      Archimandritis A, Spiliadis C, Tzivras M, et al. Gastric epithelial polyps: a retrospective endoscopic study of 12974 symptomatic patients. Ital J Gastroenterol 1996; 28:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/3\">",
"      Jalving M, Koornstra JJ, Wesseling J, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/4\">",
"      Morais DJ, Yamanaka A, Zeitune JM, Andreollo NA. Gastric polyps: a retrospective analysis of 26,000 digestive endoscopies. Arq Gastroenterol 2007; 44:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/5\">",
"      Ginsberg GG, Al-Kawas FH, Fleischer DE, et al. Gastric polyps: relationship of size and histology to cancer risk. Am J Gastroenterol 1996; 91:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/6\">",
"      Papa A, Cammarota G, Tursi A, et al. Management of gastric polyps: the need of polypectomy also for small polyps. Am J Gastroenterol 1997; 92:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/7\">",
"      Muehldorfer SM, Stolte M, Martus P, et al. Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study. Gut 2002; 50:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/8\">",
"      Yoon WJ, Lee DH, Jung YJ, et al. Histologic characteristics of gastric polyps in Korea: emphasis on discrepancy between endoscopic forceps biopsy and endoscopic mucosal resection specimen. World J Gastroenterol 2006; 12:4029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/9\">",
"      Akahoshi K, Yoshinaga S, Fujimaru T, et al. Endoscopic resection with hypertonic saline-solution-epinephrine injection plus band ligation for large pedunculated or semipedunculated gastric polyp. Gastrointest Endosc 2006; 63:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/10\">",
"      Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/11\">",
"      Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/12\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/13\">",
"      Eidt S, Stolte M. Gastric glandular cysts--investigations into their genesis and relationship to colorectal epithelial tumors. Z Gastroenterol 1989; 27:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/14\">",
"      Cappell MS, Fiest TC. A multicenter, multiyear, case-controlled study of the risk of colonic polyps in patients with gastric polyps. Are gastric adenomas a new indication for surveillance colonoscopy? J Clin Gastroenterol 1995; 21:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/15\">",
"      Dickey W, Kenny BD, McConnell JB. Prevalence of fundic gland polyps in a western European population. J Clin Gastroenterol 1996; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/16\">",
"      Stolte M. Clinical consequences of the endoscopic diagnosis of gastric polyps. Endoscopy 1995; 27:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/17\">",
"      Snover DC. Benign epithelial polyps of the stomach. Pathol Annu 1985; 20 Pt 1:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/18\">",
"      Hattori T. Morphological range of hyperplastic polyps and carcinomas arising in hyperplastic polyps of the stomach. J Clin Pathol 1985; 38:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/19\">",
"      Stolte M, Sticht T, Eidt S, et al. Frequency, location, and age and sex distribution of various types of gastric polyp. Endoscopy 1994; 26:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/20\">",
"      Dirschmid K, Platz-Baudin C, Stolte M. Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? Virchows Arch 2006; 448:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/21\">",
"      Al-Haddad M, Ward EM, Bouras EP, Raimondo M. Hyperplastic polyps of the gastric antrum in patients with gastrointestinal blood loss. Dig Dis Sci 2007; 52:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/22\">",
"      Kumar A, Quick CR, Carr-Locke DL. Prolapsing gastric polyp, an unusual cause of gastric outlet obstruction: a review of the pathology and management of gastric polyps. Endoscopy 1996; 28:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/23\">",
"      Daibo M, Itabashi M, Hirota T. Malignant transformation of gastric hyperplastic polyps. Am J Gastroenterol 1987; 82:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/24\">",
"      Orlowska J, Jarosz D, Pachlewski J, Butruk E. Malignant transformation of benign epithelial gastric polyps. Am J Gastroenterol 1995; 90:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/25\">",
"      Antonioli DA. Precursors of gastric carcinoma: a critical review with a brief description of early (curable) gastric cancer. Hum Pathol 1994; 25:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/26\">",
"      Gotoh Y, Fujimoto K, Sakata Y, et al. Poorly differentiated adenocarcinoma in a gastric hyperplastic polyp. South Med J 1996; 89:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/27\">",
"      Zea-Iriarte WL, Sekine I, Itsuno M, et al. Carcinoma in gastric hyperplastic polyps. A phenotypic study. Dig Dis Sci 1996; 41:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/28\">",
"      Dijkhuizen SM, Entius MM, Clement MJ, et al. Multiple hyperplastic polyps in the stomach: evidence for clonality and neoplastic potential. Gastroenterology 1997; 112:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/29\">",
"      Ljubici N, Bani M, Kujundzi M, et al. The effect of eradicating Helicobacter pylori infection on the course of adenomatous and hyperplastic gastric polyps. Eur J Gastroenterol Hepatol 1999; 11:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/30\">",
"      Ohkusa T, Takashimizu I, Fujiki K, et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann Intern Med 1998; 129:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/31\">",
"      Stolte M, Bethke B, Seifert E, et al. Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment. Z Gastroenterol 1995; 33:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/32\">",
"      Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995; 76:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/33\">",
"      Worthley DL, Phillips KD, Wayte N, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 2012; 61:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/34\">",
"      Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009; 137:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/35\">",
"      Kazantsev GB, Schwesinger WH, Heim-Hall J. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Gastrointest Endosc 2002; 55:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/36\">",
"      el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/37\">",
"      Modlin IM, Gilligan CJ, Lawton GP, et al. Gastric carcinoids. The Yale Experience. Arch Surg 1995; 130:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/38\">",
"      Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998; 110:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/39\">",
"      Watanabe N, Seno H, Nakajima T, et al. Regression of fundic gland polyps following acquisition of Helicobacter pylori. Gut 2002; 51:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/40\">",
"      Domizio P, Talbot IC, Spigelman AD, et al. Upper gastrointestinal pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. J Clin Pathol 1990; 43:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/41\">",
"      Genta RM, Schuler CM, Robiou CI, Lash RH. No association between gastric fundic gland polyps and gastrointestinal neoplasia in a study of over 100,000 patients. Clin Gastroenterol Hepatol 2009; 7:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/42\">",
"      Bertoni G, Sassatelli R, Nigrisoli E, et al. Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis. Ital J Gastroenterol Hepatol 1999; 31:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/43\">",
"      Declich P, Ambrosiani L, Bellone S, et al. Fundic gland polyps: a not so innocuous entity worth a careful evaluation. Am J Gastroenterol 1998; 93:2641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/44\">",
"      Wu TT, Kornacki S, Rashid A, et al. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol 1998; 22:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/45\">",
"      Abraham SC, Nobukawa B, Giardiello FM, et al. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol 2000; 157:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/46\">",
"      Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992; 102:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/47\">",
"      Marcello PW, Asbun HJ, Veidenheimer MC, et al. Gastroduodenal polyps in familial adenomatous polyposis. Surg Endosc 1996; 10:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/48\">",
"      Sawada T, Muto T. Role of upper gastrointestinal surveillance in patients with familial adenomatous polyposis. Gastrointest Endosc Clin N Am 1997; 7:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/49\">",
"      Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000; 24:167.",
"     </a>",
"    </li>",
"    <li>",
"     Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System, IARC Press, Lyon 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/51\">",
"      Rugge M, Nitti D, Farinati F, et al. Non-invasive neoplasia of the stomach. Eur J Gastroenterol Hepatol 2005; 17:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/52\">",
"      Oehlert W, Keller P, Henke M, Strauch M. Gastric mucosal dysplasia: what is its clinical significance? Front Gastrointest Res 1979; 4:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/53\">",
"      Tomasulo J. Gastric polyps. Histologic types and their relationship to gastric carcinoma. Cancer 1971; 27:1346.",
"     </a>",
"    </li>",
"    <li>",
"     Japanese classification of gastric carcinoma, Kanehara &amp; Company, Ltd, Tokyo 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/55\">",
"      Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003; 52:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/56\">",
"      de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008; 134:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/57\">",
"      Lansdown M, Quirke P, Dixon MF, et al. High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut 1990; 31:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/58\">",
"      Kolodziejczyk P, Yao T, Oya M, et al. Long-term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis. Cancer 1994; 74:2896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/59\">",
"      Nakamura K, Sakaguchi H, Enjoji M. Depressed adenoma of the stomach. Cancer 1988; 62:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/60\">",
"      Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988; 1:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/61\">",
"      Elsborg L, J&oslash;rgensen F. Sucralfate versus cimetidine in reflux oesophagitis. A double-blind clinical study. Scand J Gastroenterol 1991; 26:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/62\">",
"      Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/63\">",
"      Solcia E, Fiocca R, Villani L, et al. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995; 19 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/64\">",
"      Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994; 73:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/65\">",
"      Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993; 104:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/66\">",
"      Bordi C. Endocrine tumours of the stomach. Pathol Res Pract 1995; 191:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/67\">",
"      Debelenko LV, Emmert-Buck MR, Zhuang Z, et al. The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 1997; 113:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/68\">",
"      Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2361/abstract/69\">",
"      Borch K, Ahr&eacute;n B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2518 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-118.97.94.19-E6249A1558-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2361=[""].join("\n");
var outline_f2_19_2361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HYPERPLASTIC POLYPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Malignant potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FUNDIC GLAND POLYPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Malignant potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GASTRIC ADENOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Malignant potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GASTRIC CARCINOID TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Malignant potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2518\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2518|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/20/17743\" title=\"diagnostic image 1\">",
"      Hyperplastic gastric polyps UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2518|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/53/10064\" title=\"picture 1\">",
"      Endosc gastric adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/35/13887\" title=\"picture 2\">",
"      Gastric hyperplastic polyp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/18/18720\" title=\"picture 3A\">",
"      Endosc fundic gland polyp A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/63/10224\" title=\"picture 3B\">",
"      Endosc fundic gland polyp B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/45/42713\" title=\"picture 4\">",
"      Hyperplast gastric polyp Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/38/6754\" title=\"picture 5\">",
"      Polyp prolapsing pylorus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/17/21782\" title=\"picture 6\">",
"      Fundic gland polyp Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/58/39843\" title=\"picture 7\">",
"      Fundic gland polyps CPC Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/47/40694\" title=\"picture 8\">",
"      Gastric adenoma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/28/19906\" title=\"picture 9\">",
"      Endosc gastric carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/62/14311\" title=\"picture 10\">",
"      Gastric carcinoid poorly diff",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2518|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/44/44747\" title=\"table 1\">",
"      ASGE guidelines gastric polyps",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=related_link\">",
"      Classification and diagnosis of gastritis and gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=related_link\">",
"      Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33194?source=related_link\">",
"      Pathology and molecular pathogenesis of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_19_2362="Cataract in adults";
var content_f2_19_2362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cataract in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/19/2362/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2362/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/19/2362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2362/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/19/2362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/19/2362/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/19/2362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataract is the leading cause of blindness in the world [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/1\">",
"     1",
"    </a>",
"    ]. A cataract is an opacity of the lens of the eye that causes partial or total blindness. The word derives from the Latin \"catarractes,\" which means \"waterfall;\" to the naked eye of an observer, the foamy white opacity of an advanced cataract, seen through the pupil, resembles the turbulent water of a waterfall.",
"   </p>",
"   <p>",
"    Modern microsurgical technique allows intervention for cataract before it has resulted in blindness; normal vision typically is restored with intraocular lens implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/2\">",
"     2",
"    </a>",
"    ]. Except in certain very uncommon situations, delay in treatment does not result in an adverse outcome. The major advances in the surgical treatment of cataract in the last century have not been matched by advances in the understanding of cataract formation, in approaches to prevention, or in nonsurgical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic models estimate that there are approximately 30 million blind people in the world, 50 percent of whom are blind due to cataracts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/3\">",
"     3",
"    </a>",
"    ]. The pattern and rate of blinding disorders is different in developed and developing nations depending upon whether nutritional and infectious causes of blindness are eradicated, and whether there are resources available for treatable disorders such as cataract.",
"   </p>",
"   <p>",
"    The definition of blindness is different for international health purposes than it is for social and rehabilitative purposes in the United States. The least developed nations are estimated to have a 1 percent rate of blindness using the international definition; developed nations are thought to have a 0.2 percent rate of blindness. Blindness by international health standards is defined as the inability to count fingers at 10 feet; this converts to",
"    <span class=\"nowrap\">",
"     10/200",
"    </span>",
"    by Snellen notation, which means that a patient can see at 10 feet what a normal person would see at 200 feet. This level of vision allows ambulation but does not allow the reading of print of any size. The standard for legal blindness in the US is",
"    <span class=\"nowrap\">",
"     20/200.",
"    </span>",
"    This standard is lower than the international standard, meaning it is easier to qualify as \"blind.\" Individuals with",
"    <span class=\"nowrap\">",
"     20/200",
"    </span>",
"    vision can ambulate, and some can read print with appropriate low-vision aids.",
"   </p>",
"   <p>",
"    The Eye Diseases Prevalence Research Group (EDPRG) estimated causes of blindness and visual impairment in the US by applying the results of population-based studies conducted in North America, Western Europe, and Australia between 1990 and 2001 to the population structure of the US based on the year 2000 census [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/4\">",
"     4",
"    </a>",
"    ]. The EDPRG estimated that 0.78 percent of people older than age 40 in the US were blind by the US definition and an additional 1.98 percent had low vision, with a best corrected visual acuity between",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     20/200.",
"    </span>",
"    Cataract was associated with approximately 50 percent of cases of low vision. Using a definition of cataract that did not require visual impairment, the EDPRG estimated that in 2000 there were 20.5 million people over 40 in the US (17.2 percent) with cataract in either eye and projected that this number would rise to 30.1 million by 2020 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 10-year incidence of cataract has been reported as 72 percent from a longitudinal study of people over age 49 in Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/6\">",
"     6",
"    </a>",
"    ] and 54 percent for a US population aged 43 to 86 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryonic development and lifelong growth of the lens of the eye produce a structure composed of specialized cells arranged in a highly ordered complex manner. These cells are stratified epithelia and have a very high content of cytoplasmic protein. These proteins, the crystallins, along with the complex structure, impart transparency to the lens.",
"   </p>",
"   <p>",
"    Unlike other epithelia, the lens does not shed its nonviable cells. Thus, it is particularly susceptible to the degenerative effects of aging on cell structure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/8\">",
"     8",
"    </a>",
"    ]. Some of the anatomic and ultrastructural correlates of lens opacity are known, although exact pathogenetic mechanisms are not. Epidemiologic and experimental evidence suggests that photo-oxidative insult, perhaps potentiated by toxic or sensitizing substances, plays a role.",
"   </p>",
"   <p>",
"    The vast majority of cataract extractions are for acquired cataract, with senile or age-related cataract predominating. Risk factors associated with acquired cataract in developed nations include [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Alcohol consumption",
"     </li>",
"     <li>",
"      Sunlight exposure",
"     </li>",
"     <li>",
"      Low education",
"     </li>",
"     <li>",
"      Poor lifestyle habits, including malnutrition and physical inactivity",
"     </li>",
"     <li>",
"      Metabolic syndrome",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Systemic corticosteroid use and possibly prolonged administration of high doses of inhaled corticosteroids (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"       \"Major side effects of inhaled glucocorticoids\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these risk factors are environmental stressors that lead to the formation of toxins or the impairment of antioxidants, although low education has no obvious biologic link. A dose-response relationship with cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/11\">",
"     11",
"    </a>",
"    ] and ultraviolet-B exposure in sunlight [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/12\">",
"     12",
"    </a>",
"    ] has been demonstrated; the size of the risk associated with duration of exposure to diabetes has not been quantified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/9\">",
"     9",
"    </a>",
"    ]. Assuming a roughly two-fold increased risk of cataract associated with smoking, approximately 20 percent of cataract cases are attributable to smoking in the US population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/11\">",
"     11",
"    </a>",
"    ]. Some damage to the lens caused by smoking may be reversible upon quitting, although the reduction in cataract risk associated with smoking cessation is primarily due to limiting further dose-related damage to the lens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other environmental stressors may be involved as well. Low-level accumulated lead exposure, at levels commonly experienced by adults in the US, appears to be associated with an increased risk of cataract [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other generally accepted causes of acquired or secondary cataract include ocular trauma (traumatic cataract), uveitis, scleritis (particularly necrotizing scleritis), radiation of an intraocular tumor, systemic disease such as myotonic dystrophy, and use of topical corticosteroids, certain phenothiazines, and topical anticholinesterases (toxic cataract).",
"   </p>",
"   <p>",
"    The indication for surgical intervention in these types of acquired cataract is the same as for age-related cataract (see below). Some forms of acquired cataract, such as that related to trauma or uveitis, require modification of standard surgical technique, but in most cases special surgical considerations are not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of age-related cataract is a painless, progressive process that is highly variable among individuals. Cataract formation typically is bilateral, although it is often asymmetrical. Patients usually complain of a problem with night driving, reading road signs, or difficulty with fine print.",
"   </p>",
"   <p>",
"    In many cases there is an increase in nearsightedness before there is opacity of the lens that degrades vision. This increase in nearsightedness, called a \"myopic shift,\" is caused by an increase in the refractive power of a lens that is gradually becoming cataractous and can continue as opacity develops. The myopic shift may be correctable with a change in spectacle correction; the lens opacity is not correctable in this manner. Surgery should be deferred as long as diminished acuity can be corrected with spectacles to meet a patients needs; in rare cases the patient may not tolerate the full correction of refractive error because the result is imbalanced with respect to the fellow eye, and cataract surgery is chosen without first dispensing full correction (see below).",
"   </p>",
"   <p>",
"    Age-related cataract typically has three components: nuclear sclerosis (",
"    <a class=\"graphic graphic_picture graphicRef51557 \" href=\"UTD.htm?30/16/30990\">",
"     picture 1",
"    </a>",
"    ); cortical spoking (",
"    <a class=\"graphic graphic_picture graphicRef56676 \" href=\"UTD.htm?35/46/36590\">",
"     picture 2",
"    </a>",
"    ); and posterior subcapsular haze (",
"    <a class=\"graphic graphic_picture graphicRef72677 \" href=\"UTD.htm?0/25/414\">",
"     picture 3",
"    </a>",
"    ). Each affects a different anatomical part of the lens and has different symptoms and progression, although the indication for intervention with all types is the same (",
"    <a class=\"graphic graphic_figure graphicRef70532 \" href=\"UTD.htm?33/4/33859\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nuclear cataract: Nuclear cataract progresses very slowly. Distance vision typically is affected much more than near vision. It is not unusual to find individuals in their 80s with nuclear cataract degrading acuity to the",
"      <span class=\"nowrap\">",
"       20/70",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       20/100",
"      </span>",
"      level, with near vision preserved at the",
"      <span class=\"nowrap\">",
"       20/25",
"      </span>",
"      level. Such an individual may not be particularly aware of or bothered by the decreased vision from cataract if he or she does not drive. Nuclear cataract also dulls colors and white significantly; this is rarely a patient complaint until after the first cataract is removed, at which time the effect on color is noted by comparison with the brightness of colors in the operated eye.",
"     </li>",
"     <li>",
"      Cortical cataract: Although it is a prominent finding on biomicroscopic examination, cortical cataract does not degrade vision very much.",
"     </li>",
"     <li>",
"      Posterior subcapsular cataract (PSC): PSC tends to cause disabling glare in bright sunlight and from headlights, even if visual acuity is degraded only slightly. Systemic and topical steroid use is associated with formation of this type of cataract. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .) PSC cataract tends to progress more quickly than nuclear cataract (over a period of months rather than years); the explanation for this pattern of progression is not known.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A cataract that still allows a view of the retina and transmits a red reflex is called an immature cataract (",
"    <a class=\"graphic graphic_picture graphicRef53639 \" href=\"UTD.htm?1/29/1503\">",
"     picture 4",
"    </a>",
"    ); once the red reflex is lost it is called mature (",
"    <a class=\"graphic graphic_picture graphicRef71657 \" href=\"UTD.htm?30/30/31200\">",
"     picture 5",
"    </a>",
"    ). A mature cataract degrades vision to the",
"    <span class=\"nowrap\">",
"     20/400",
"    </span>",
"    level or worse. A hypermature cataract is one in which the cortex of the lens has liquefied and the lens nucleus is mobile within the capsule (",
"    <a class=\"graphic graphic_picture graphicRef62426 \" href=\"UTD.htm?19/55/20351\">",
"     picture 6",
"    </a>",
"    ). A moderate to advanced cataract can interfere with the diagnosis and therapy of diseases involving the retina and optic nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Secondary glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small fraction of mature and hypermature cataracts can give rise to secondary glaucoma. Three rare types of intractable glaucoma may occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phacolytic glaucoma in which lysed lens proteins cause a pressure rise",
"     </li>",
"     <li>",
"      Phacoanaphylactic glaucoma in which the autoimmune reaction to these proteins causes a pressure rise",
"     </li>",
"     <li>",
"      Phacomorphic glaucoma in which the swollen lens causes a form of angle closure glaucoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These types of glaucoma cause a red, painful eye; they are not asymptomatic like many other glaucomas. Since this complication is not subtle, the presence of a mature cataract is not necessarily an indication for cataract surgery if it remains asymptomatic in a patient who for other reasons had little useful vision in the affected eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataract should be suspected in any patient who complains of a painless, progressive decline in vision. A lens opacity can be confirmed by a nondilated fundus examination with the direct ophthalmoscope; there may be darkening of the red reflex, opacities within the red reflex, or obscuration of ocular fundus detail. In the absence of other visual symptoms, a red eye, or other abnormality noted on fundus examination, these patients should be referred on a nonurgent basis for comprehensive ophthalmic examination.",
"   </p>",
"   <p>",
"    A comprehensive ophthalmologic examination begins with a history of visual complaints, including the patient's ability to meet his or her visual needs. Subjective refraction should be attempted to monitor for myopic shift and to see if a change in spectacles would improve vision. The type and extent of lens opacity is noted, and a dilated fundus examination is performed to rule out the presence of other pathology that could account for diminished vision. A diagnosis of visually significant cataract is made if no other pathology is detected and the degree of lens opacity correlates with the patient's complaints and best-corrected visual acuity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=see_link\">",
"     \"Slit lamp examination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of cataract occur in patients over age 60 or in younger individuals who have risk factors such as diabetes mellitus, systemic steroid use, or a history of significant eye trauma (see above); these individuals should be and are typically seen annually by an ophthalmologist to monitor for asymptomatic conditions such as open-angle glaucoma and diabetic retinopathy. Patients with known cataract and no specific complaint are followed at intervals determined by their risk for glaucoma or other eye disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven therapy to either prevent cataract formation or slow progression of lens opacity once it develops. However, observational studies suggest that some interventions may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eating a healthy diet is associated with a lower risk of developing nuclear cataract in women [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/15\">",
"       15",
"      </a>",
"      ]. Healthy diet in this study was based on US dietary guidelines from the 1992 food pyramid which places emphasis on major food groups (grains, vegetables, fruits, milk, meat), as well as",
"      <span class=\"nowrap\">",
"       total/saturated",
"      </span>",
"      fat, cholesterol, and sodium intake.",
"     </li>",
"     <li>",
"      Diets rich in lutein and zeaxanthin are associated with a decrease in the prevalence of cataracts in older women [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/16\">",
"       16",
"      </a>",
"      ]. This relationship might reflect other benefits of diets high in fruits and vegetables, or lifestyle factors associated with such a diet.",
"     </li>",
"     <li>",
"      Smoking cessation may prevent cataract formation, as smoking is associated with a higher risk of developing nuclear cataract [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postmenopausal estrogen use (longer than 10 years) may reduce the risk of nuclear cataracts, although there are significant concerns about the long-term use of estrogen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"       \"Postmenopausal hormone therapy: Benefits and risks\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several interventions that have been suggested for prevention have not been proven to prevent cataracts. There is no evidence that any particular type of sunglasses is effective or superior in the prevention of cataract or slowing cataract progression. Increased dietary glycemic load is not associated with risk for cataract [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/17\">",
"     17",
"    </a>",
"    ], and no studies have been performed to evaluate whether blood sugar control in patients with diabetes correlates with cataract risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Vitamin supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized trials and observational studies have investigated whether antioxidant vitamin supplementation can prevent cataracts. A systematic review and meta-analysis of nine randomized trials evaluating one or more antioxidant vitamins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    , vitamin C, and vitamin E) for at least one year, with follow-up for 2 to 12 years, found no evidence that vitamin supplementation reduced the risk of cataract or of cataract extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/18\">",
"     18",
"    </a>",
"    ]. &nbsp;There is no convincing evidence that vitamins are effective [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREOPERATIVE MEDICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataract surgery is a low-risk procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/20\">",
"     20",
"    </a>",
"    ], but the surgery is typically performed on older adults. In this population, multiple medical morbidities increase the risk of any procedure. In a systematic review of 21,531 total cataract surgeries, 707 adverse medical events related to the surgery were reported, resulting in 3 deaths and 61 hospitalizations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preoperative testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining a routine \"battery\" of tests is not necessary in patients undergoing cataract extraction. A systematic review of three randomized trials (21,531 cataract surgeries) found that routine preoperative medical testing increased surgical costs but did not reduce the risk of intraoperative or postoperative medical adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/21\">",
"     21",
"    </a>",
"    ]. The largest trial among the three involved 19,557 surgeries and reported complication rates of 31.3 events per 1000 operations for patients randomly assigned either to testing or no routine testing; results did not differ when stratified by age, sex, race, or physical status [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative blood pressure control is important to avoid complications such as suprachoroidal hemorrhage. Patients should be given their antihypertensive medications with a sip of water on the morning of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked derangement of glycemic control is uncommon in patients with diabetes who undergo cataract surgery since the procedure is brief. Patients with diabetes should preferably undergo surgery in the early morning to avoid hypoglycemia; insulin or oral hypoglycemic drugs can then be held until after surgery. If patients with type 1 diabetes are scheduled later in the morning or afternoon, one-third to one-half of the morning insulin dose can be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study of stable patients with a history of prior myocardial infarction documented no cases of reinfarction after ophthalmic procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/23\">",
"     23",
"    </a>",
"    ]. Nevertheless, patients with coronary heart disease should continue all antianginal medications, except possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Aspirin and other antiplatelet agents'",
"    </a>",
"    below), up to the time of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Upper respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective cataract surgery should be postponed in patients with an acute upper respiratory infection since cough may pose some risk during the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocarditis prophylaxis is not necessary in patients undergoing cataract surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antithrombotic agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Aspirin and other antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2008 anticoagulation guidelines from the American College of Chest Physicians (ACCP) recommend that patients who are receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and are undergoing cataract removal continue to receive aspirin around the time of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risks associated with either continuing or stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    appear to be very small [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In a prospective cohort study of 19,584 cataract surgeries in patients 50 years of age and older, there were 4517 patients routinely taking aspirin prior to surgery, of whom 3363 continued aspirin within 14 days of surgery and 977 discontinued aspirin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/25\">",
"     25",
"    </a>",
"    ]. The rate of ocular hemorrhagic events in patients who continued aspirin was similar to that in patients not routinely taking aspirin (0.56 versus 0.59 events per 1000 surgeries). Patients who discontinued aspirin prior to surgery also had no evidence of increased stroke, TIA, or thromboembolic events compared with those who continued aspirin (1.02 versus 1.49 per 1000 surgeries) and had a somewhat lower rate of myocardial ischemia and infarction (1.02 versus 5.06 per 1000 surgeries).",
"   </p>",
"   <p>",
"    The higher rate of events in those who continued",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    suggests that there was confounding in the study in that those who discontinued aspirin were probably a lower risk group at baseline. Nevertheless, the overall risk of stopping aspirin is likely to be very low in the majority of patients despite this.",
"   </p>",
"   <p>",
"    Individual patient characteristics may sway the decision to maintain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or NSAID therapy. If a patient has suffered a bleeding complication in the fellow eye, an attempt should be made to reduce the risk factors for bleeding, including the use of aspirin and NSAIDs.",
"   </p>",
"   <p>",
"    Limited data are available regarding the risk of bleeding with cataract surgery in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Consideration should be given to delaying cataract surgery until the minimum period of dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus clopidogrel) has passed for patients receiving therapy for prevention of stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H11#H11\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Early noncardiac surgery or gastrointestinal endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cardiovascular disease who take thienopyridine agents chronically, for reasons other than the prevention of coronary artery stent thrombosis, are at increased risk for acute cardiovascular events when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ) is discontinued. However, these medications should probably be discontinued five to seven days before surgery, and resumed as early as possible in the postoperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks associated with either continuing or stopping",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    appear to be small [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/25,27-30\">",
"     25,27-30",
"    </a>",
"    ]. In a prospective cohort study of 19,584 cataract surgeries in patients 50 years of age and older, there were 681 patients routinely taking warfarin prior to surgery, of whom 526 continued warfarin within four days of surgery and 208 discontinued warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/25\">",
"     25",
"    </a>",
"    ]. There were no ocular hemorrhagic events whether warfarin was continued or discontinued and no significant differences in overall medical event rates.",
"   </p>",
"   <p>",
"    The 2008 anticoagulation guidelines from the ACCP recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    be continued for patients undergoing cataract removal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/24\">",
"     24",
"    </a>",
"    ]. Individual considerations, however, should take into account the reason for anticoagulation, whether the patient is monocular or binocular, or has risk factors for suprachoroidal hemorrhage (eg prior hemorrhage in the fellow eye).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Alpha blockers/IFIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFIS is a surgical condition characterized by a triad of findings: a flaccid iris billowing through the surgical incision, iris prolapse, and intraoperative pupillary constriction. IFIS both complicates the surgical procedure, and increases risk for postoperative complications (retinal detachment and endophthalmitis) related to posterior capsular rupture and lens fragments within the vitreous.",
"   </p>",
"   <p>",
"    Some patients treated with alpha-1-antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    ) have developed intraoperative floppy iris syndrome (IFIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/31-36\">",
"     31-36",
"    </a>",
"    ]. In one series, floppy iris syndrome was reported at cataract surgery in 25 of 58 eyes (50 patients) taking tamsulosin and 4 or 21 eyes (19 patients) taking naftopidil systemically [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/33\">",
"     33",
"    </a>",
"    ]. It may affect 2 to 3 percent of all cataract operations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     Tamsulosin",
"    </a>",
"    , with particular affinity for the alpha 1a receptor, has particularly been associated with IFIS. A nested case control study of men aged 66 or older who had cataract surgery between 2002 and 2007 found that the risk of adverse events requiring a second procedure within 14 days of the initial cataract surgery was 2.3 times greater for those exposed to tamsulosin within two weeks of surgery (OR 2.33, 95% CI 1.22-4.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/34\">",
"     34",
"    </a>",
"    ]. There was no significant association of adverse events with other alpha blockers or with earlier exposure to tamsulosin. However, the authors do not conclude that their data definitively support either stopping tamsulosin prior to surgery, or switching to another alpha blocker.",
"   </p>",
"   <p>",
"    Poor pupillary dilation in patients receiving alpha-1-antagonists can be a clue that IFIS physiology has developed. IFIS has been reported as well in patients not taking alpha blockers, though other associated factors have not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be asked about use of alpha-1-antagonists during the preoperative evaluation. Clinical impression is that the drug effect is long-lasting (weeks, months, or years), and most eye surgeons do not insist that these agents be discontinued. Various preoperative and intraoperative regimens can reduce IFIS (eg preoperative cycloplegia, low flow fluids, iris retractors and pupillary ring expanders); the rate of posterior capsule rupture was only 0.6 percent, using one of several IFIS management strategies, in a multicenter study of 167 cataract surgeries performed in patients for whom experienced surgeons were aware that the patient had taken",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/35\">",
"     35",
"    </a>",
"    ]. It is therefore important to make sure the surgeon is aware that the patient was receiving such a medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only treatment for cataract is to surgically remove and replace the opacified lens from the eye to restore transparency of the visual axis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern surgical technique is extremely safe with few major complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/38\">",
"     38",
"    </a>",
"    ], and the intraocular lens allows rehabilitation of one eye so that it is compatible with vision in the fellow eye with the natural lens. Surgery currently is indicated if symptoms from the cataract interfere with the patient's ability to meet his or her needs of daily living; there are no criteria based upon the level of visual acuity. There is no technical advantage to taking out a cataract sooner. Except in cases in which cataract limits monitoring for retinal or optic nerve disease, or in the rare instance in which it is inducing glaucoma, the choice of whether to pursue surgery should be determined by the informed patient rather than the surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the development of modern intraocular lenses and surgical techniques, patients were often told that they must wait for surgery until their cataract was \"ripe.\" This is no longer necessary. Surgery involved greater risk to the eye and required several weeks of immobilization. The residual refractive error in an aphakic eye (without a lens), required thick spectacles for correction which had optical features that caused peripheral distortion and caused images to \"jump\" into the field of view (",
"    <a class=\"graphic graphic_picture graphicRef71082 \" href=\"UTD.htm?27/22/28015\">",
"     picture 7",
"    </a>",
"    ). In addition, aphakic correction of one eye is poorly tolerated if the other eye has useful phakic vision because of magnification disparity between the two eyes. For these reasons, cataract extraction in that era was deferred until the vision was poor enough (less than",
"    <span class=\"nowrap\">",
"     20/200,",
"    </span>",
"    which correlated to legal blindness) to take on the risk of cataract surgery, and until vision in the other eye was poor enough to warrant surgery soon after the first eye.",
"   </p>",
"   <p>",
"    The ophthalmologist must assess what proportion or aspect of diminished vision is accounted for by cataract in the presence of coexistent pathology such as age-related macular degeneration, glaucoma, or diabetic retinopathy. Even if it seems that cataract accounts only partially for loss of vision, surgery may be indicated if the other disease process is under control and the patient understands that the prognosis for complete recovery of visual acuity is guarded. Many patients with impaired vision from cataract and age-related macular degeneration or diabetic retinopathy do have significant improvement in visual function after cataract extraction, even when coexistent retinal disease precludes recovery of",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    vision. Adjunctive tests that can be done preoperatively, such as the PAM (potential acuity meter), may provide useful information to the ophthalmologist in advising whether cataract surgery is likely to yield improvement in vision in patients with coexistent pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Surgery on second eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about health care expenditures have raised questions regarding the value of performing cataract surgery on a second eye after successful surgery on the first eye. One randomized study found only slight differences in binocular vision in patients who received a second surgery versus those whose second surgery was delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there were major benefits for the second surgery group in terms of reported visual symptoms and quality of life. A retrospective population-based study found that visual outcomes were significantly better for bilateral, compared to unilateral, cataract surgery only when the second eye had a significant cataract or poor visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/41\">",
"     41",
"    </a>",
"    ]. Another analysis concluded that surgery on a second eye is highly cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataract surgery typically is performed on an outpatient basis at a hospital or ambulatory surgicenter [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Medicare will not pay for perioperative hospitalization unless there is a medical problem requiring active management or the patient is blind in the fellow eye. General anesthesia is necessary only for patients who cannot reliably cooperate under local anesthesia, (eg cognitive impairment or other communication barrier) or possibly those who had a complication of local anesthesia in the fellow eye.",
"   </p>",
"   <p>",
"    Local anesthesia is provided by retro- or peribulbar injection, sub-Tenon's infusion, intra-cameral instillation, or topical anesthetic. All forms are typically carried out under monitored intravenous sedation. Topical and intra-cameral anesthesia avoid the risk of injection-related trauma to the optic nerve and globe, but have the disadvantage of not providing paralysis of the extraocular muscles. In a 2002-2003 survey of ophthalmologists in the UK, 7 of 8 serious neurologic complications (neurologic deficits attributed to the effects of local anesthesia on the brainstem) among an estimated 375,000 procedures were reported with peribulbar or retrobulbar anesthesia; the lowest rates of sight- or life-threatening complications were with sub-Tenon's, topical, and intra-cameral anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/45\">",
"     45",
"    </a>",
"    ]. A 2007 systematic review of seven studies (617 patients, 742 eyes) concluded that sub-Tenon anesthesia provided better pain relief and lower risk for posterior capsule tear or vitreous loss than topical anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/46\">",
"     46",
"    </a>",
"    ]. A 2012 systematic review of 15 studies also found better pain relief but more anesthesia-related complications for retrobulbar or peribulbar anesthesia, compared to topical anesthesia, and no difference in surgery-related complications or outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although commonly prescribed, there is little evidence to support the use of topical antibiotics to decrease the risk of endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/48\">",
"     48",
"    </a>",
"    ]. Routine use of third or fourth generation fluoroquinolones for this purpose may increase the risk of emerging antibiotic resistance.",
"   </p>",
"   <p>",
"    Two techniques are most commonly used for cataract extraction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard extracapsular cataract extraction (ECCE) typically involves removal of the lens nucleus in one piece. This necessitates an incision of approximately 10 to 14 mm, which represents 5 clock hours or 150 degrees. The lens cortex is aspirated from the eye and the lens capsule is left behind to support an intraocular lens. A rigid plastic lens with an optic diameter of 6 to 7 mm is inserted through the same incision and placed on or in the capsule, behind the iris.",
"     </li>",
"     <li>",
"      In phacoemulsification, also called small incision surgery, the lens is fragmented using ultrasound energy and aspirated from the eye through a smaller 2 to 4 mm incision. The cortex is aspirated and the lens capsule is left behind as in extracapsular cataract extraction. A foldable plastic or silicone lens may be passed through the smaller incision, or the incision can be extended to 5 to 7 mm to accommodate a larger, rigid plastic lens. The small incision may be self-sealing, requiring one or even no sutures. Phacoemulsification has the advantage of more rapid visual recovery due to the small incision size, and decreased likelihood of suture-induced astigmatism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intracapsular cataract extraction (ICCE), an approach to cataract surgery in which typically no lens implant is placed in the eye, is still common in developing countries, but is rarely performed in the US since the 1970s.",
"   </p>",
"   <p>",
"    While phacoemulsification is commonly performed in developed countries, it is technology-dependent and relatively costly. These factors create barriers to care in the developing world, where cataracts cause 50 to 80 percent of blindness. A systematic review of surgical interventions for age-related cataract found outcomes with phacoemulsification were superior to ECCE with sutures, and that ECCE with a lens implant provides better visual outcome than intracapsular cataract extraction (ICCE) with aphakic glasses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative procedure, called manual small incision cataract surgery (MSICS) or sutureless small-incision extracapsular cataract surgery (SICS) has been developed and has many of the advantages of phacoemulsification without the costs. A systematic review of three randomized trials in Nepal and India comparing short-term outcomes of MSICS and ECCE found better visual acuity with MSICS, though overall good functional visual acuity was achieved in less than half of subjects with either method and complications were greater with MSICS in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/50\">",
"     50",
"    </a>",
"    ]. One randomized trial compared MSICS with phacoemulsification in 108 patients in Nepal and found similar visual acuity at six months for both groups; longer-term follow-up is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synthetic intraocular lenses are generally implanted after these procedures, except in some forms of uveitis, in very young children, in some cases of high myopia, and in the event of unusual intraoperative complications. The alternatives to lens implantation, aphakic spectacles or contact lenses, however, are unsatisfactory for most patients.",
"   </p>",
"   <p>",
"    There are two types of intraocular lenses (IOL), monofocal or multifocal, that can be implanted. The multifocal lenses are a newer option. In a 2012 systematic review of 18 trials (16 completed, 2 ongoing) that compared monofocal and multifocal lenses, improvements in distance visual acuity were similar with the two types of lenses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/52\">",
"     52",
"    </a>",
"    ]. Multifocal IOL conferred better near vision and more freedom from having to use glasses. However, patients with multifocal IOL reported more adverse visual effects (eg, haloes). Meta-analysis could not be performed because of methodologic and statistical heterogeneity among the trials.",
"   </p>",
"   <p>",
"    A patient may choose phacoemulsification under topical anesthesia for its apparent short-term advantages. However, there is no reason not to undergo the traditional extracapsular cataract surgery if that is the preferred technique of the ophthalmologist whom the patient has chosen for surgery. More data is required before conclusions can be drawn regarding MSICS and its equivalence to phacoemulsification or ECCE in developing or developed countries and on monofocal versus multifocal IOLs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can resume normal activity such as reading, walking, eating, and watching television the evening of surgery. The eye may be patched, depending upon whether anesthesia was local or topical. The eye is examined on the first post-operative day. Many surgeons allow resumption of driving at the level immediately prior to surgery at this time, as long as continued patching is not required.",
"   </p>",
"   <p>",
"    Recommendations on physical activity restriction vary widely among surgeons depending upon their confidence in the technique used. Patients with large incisions typically are advised not to undertake heavy lifting or strenuous activity for several weeks to several months. Surgeons who perform phacoemulsification tend to restrict activity for a period of days to weeks. Most patients are able to return to work by one week unless driving or heavy lifting is required. There are no evidence-based data for these recommendations.",
"   </p>",
"   <p>",
"    Patients typically are seen one day, one week, and one month after surgery to monitor for complications and proper healing. Corticosteroid eye drops usually are required during this period. In addition, perioperative nonsteroidal antiinflammatory drops (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    0.4%) may be advised for patients at increased risk for cystoid macular edema (diabetic retinopathy, retinal vascular or macular disease); the need for topical NSAIDs in low risk patients is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/53\">",
"     53",
"    </a>",
"    ]. Sutures are removed at 6 to 12 weeks if there is suture-induced astigmatism (much less likely with phacoemulsification).",
"   </p>",
"   <p>",
"    The final spectacle prescription is determined at any point between one and three months after surgery depending upon the need for suture removal. Patients usually require spectacles for night driving",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reading after cataract surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Complications and outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1994 review from the Cataract Outcome Team found that 95.5 percent of eyes without preexisting ocular comorbidity had postoperative visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better (the acuity necessary to obtain an unrestricted drivers license); if all eyes were included in the pool, 89.7 percent had",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    acuity or better following cataract surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of the procedure included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endophthalmitis, a complication that can result in markedly reduced vision and typically leaves some impairment, occurred in 0.13 percent. Lower rates have been noted in later series. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link&amp;anchor=H2#H2\">",
"       \"Bacterial endophthalmitis\", section on 'Acute postcataract endophthalmitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bullous keratopathy occurred in 0.3 percent.",
"     </li>",
"     <li>",
"      Intraocular lens",
"      <span class=\"nowrap\">",
"       malposition/dislocation",
"      </span>",
"      occurred in 1.1 percent.",
"     </li>",
"     <li>",
"      Clinically apparent cystoid macular edema occurred in 1.5 percent.",
"     </li>",
"     <li>",
"      Retinal detachment, which typically requires intervention in the form of laser, cryotherapy, or surgery, occurred in 0.7 percent. It can result in marked loss of vision and moderate impairment, although sometimes can be treated with no loss of vision. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=see_link\">",
"       \"Retinal detachment\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A population-based study suggested that the risk of retinal detachment is increased for up to 20 years after cataract surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/55\">",
"       55",
"      </a>",
"      ]. In one longitudinal study of 9400 patients, the cumulative rate of retinal detachment was 2.3 percent at eight years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Highly myopic eyes appear to be at particularly high risk for retinal detachment after cataract surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. Patients with a history of retinopathy of prematurity (ROP) who develop cataracts at a relatively early age are also at high risk for post operative retinal detachment; retinal tear or detachment occurred in 23 percent of 66 eyes with ROP in one retrospective series [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Posterior capsule opacification developed in 19.7 percent of patients. This \"complication\" is successfully treated with YAG laser capsulotomy, and therefore is not considered a complication by many surgeons. The procedure does increase the risk of retinal detachment, however, and cannot be considered entirely benign. A meta-analysis found that biomaterials and edge design may influence posterior capsule opacification; incidence was lower for acrylic or silicone lenses, and for those with sharp optic edges [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toxic anterior segment syndrome (TASS) is inflammation of the anterior segment of the eye, occurring typically within 24 hours of surgery and related to noninfectious contaminants of equipment, solutions, or other supplies used during the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/60\">",
"       60",
"      </a>",
"      ]. Clusters of cases have been traced to faulty preparation of sterilization equipment. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the frequency with which cataract surgery is performed in the US (1 million cases annually), even the infrequent complications affect large numbers of people. One study based on Canadian administrative claims data found that adverse events were lower for surgeons who performed more cataract procedures (adverse event rate within 14 days of surgery 0.8 percent for surgeons performing 50 to 250 cataract surgeries per year; 0.1 percent for those performing more than 1000 cataract surgeries per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reports examined the factors that were predictive of the outcome of cataract surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In one prospective cohort, age &gt;75, good visual function, low symptom score, and ocular comorbidities all independently increased the likelihood of no improvement in visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/62\">",
"     62",
"    </a>",
"    ]. In another prospective cohort study designed to create decision trees for appropriateness of cataract surgery, poor pre-intervention visual acuity and negative surgical complexity were predictors of significant improvement in visual acuity after cataract surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cataract Patient Outcome Research Team reported on the rigor of research methods in studies of the effectiveness and safety of cataract extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/64\">",
"     64",
"    </a>",
"    ]. Their review suggested that the rigor of evidence regarding the outcomes of cataract surgery performed by alternative techniques was suboptimal. In particular, most of the published studies on outcomes of cataract surgery were not designed with a control or comparison group. There were problems with patient selection bias, with lack of standardized assessment of outcome, and with lack of standard definitions of complications and measures of their clinical significance. Studies of large numbers of eyes were just as susceptible to these problems as those of smaller numbers, and the rigor of studies did not show improvement between 1979 and 1991.",
"   </p>",
"   <p>",
"    Patients can learn about cataract surgery through many media including clinicians' informational materials and advertising, the Internet, publications of the American Academy of Ophthalmology, and word of mouth. Although patients have more information available to them than ever before regarding surgical options for cataract, the scientific data to aid them and their clinicians in making these decisions are lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Risk of macular degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised that patients undergoing cataract surgery may be at increased risk for age-related macular degeneration (AMD). Proposed mechanisms include an increased susceptibility to light damage, inflammatory changes secondary to surgery, or induction of angiogenesis.",
"   </p>",
"   <p>",
"    A study that pooled data from two observational studies including 6019 patients with five years of follow-up concluded that the risk of developing late stage AMD in eyes that had undergone cataract surgery was substantially increased (odds ratio 5.7, 95% CI 2.4-13.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/65\">",
"     65",
"    </a>",
"    ]. These results may potentially be confounded by the fact that AMD and cataracts have common risk factors. The study controlled for such confounding in a multivariate model; however, residual confounding is possible. Additionally, some cases of newly diagnosed or progressed AMD following cataract surgery may represent prior disease that was not recognized because of lens opacity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/66\">",
"     66",
"    </a>",
"    ]. Further studies will be needed to define whether the association between AMD and cataract surgery is causal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cost of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of cataract surgery is born, for the most part, by Medicare, since predominantly it is performed on individuals over the age of 65. In 1990 it was the most frequently performed surgical procedure in the Medicare population; more than 1 million procedures were performed yearly in Medicare beneficiaries [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/67\">",
"     67",
"    </a>",
"    ]. One analysis projected that in 1991 Medicare spent $3.3 billion on cataract surgery (with a median allowed charge of approximately $2500 for a \"typical\" episode of cataract surgery), $39 million on preoperative ophthalmological tests, $7 million on postoperative ophthalmological tests, and more than $18 million on perioperative medical services, for a total estimated expenditure of $3.4 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/68\">",
"     68",
"    </a>",
"    ]. The rate of reimbursement to hospitals, surgicenters, and surgeons does not vary by technique used. There have been no analyses of the benefit or effectiveness of the Medicare expenditure for cataract surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16665471\">",
"    <span class=\"h2\">",
"     Cost-effectiveness of surgery and impact from population studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cataract surgery has been found to be cost-effective in its effect on quality-adjusted life years gained compared with other medical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/69\">",
"     69",
"    </a>",
"    ]. In one analysis, the cost utility for first eye cataract surgery in Western countries was calculated to range from $245 to",
"    <span class=\"nowrap\">",
"     $22,000/quality",
"    </span>",
"    adjusted life year (QALY) and from $9 to $1600 in developing countries, with variation depending on the model applied for discounting over time and the surgical costs of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cataract surgery may result in benefits for older adults, beyond improved vision and resulting improved quality of life. Data from a Medicare database, comparing hip fracture rates in patients with cataract who did or did not undergo cataract surgery, found a 16 percent decrease in the adjusted odds ratio for hip fracture within one year in patients who had surgery and a 23 percent decrease for patients with severe cataract [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/72\">",
"     72",
"    </a>",
"    ]. A cohort study suggested that cataract surgery reduces the number of motor vehicle crashes in older adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/19/2362/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the impact was relatively small (reduction of 4.74 crashes per million miles) and other confounding factors may have played a role in the outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=see_link\">",
"       \"Patient information: Age-related vision loss (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=see_link\">",
"       \"Patient information: Cataracts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cataract is an opacity of the lens of the eye that causes partial or total blindness. Fifty percent of blindness globally is estimated to be caused by cataract. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for cataract include older age, smoking, poor lifestyle habits, alcohol consumption, sunlight exposure, lower educational status, diabetes mellitus, and systemic and possibly high-dose inhaled corticosteroids. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cataract formation is usually bilateral and presents with problems with night driving, reading road signs, or difficulty with fine print. There is often an increase in myopia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cataract should be suspected in any patient who complains of painless progressive decline in vision. Most cases of cataract occur in patients over age 60 or in younger individuals who have risk factors. Diagnosis is by comprehensive eye examination; a dilated fundus examination should be performed to rule out other pathology that could account for diminished vision. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cataract surgery is a low-risk procedure. Extensive preoperative evaluation is not indicated, but blood pressure should be controlled in hypertensive patients; endocarditis prophylaxis is not necessary. The risk of bleeding with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is low, and these medications may be continued for most patients. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Preoperative medical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraoperative floppy iris syndrome (IFIS) is seen in patients treated with alpha-antagonists; it is important that the surgeon be aware when patients have been taking alpha blockers since special surgical protocols can be used to reduce risk for IFIS. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Alpha blockers/IFIS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is indicated when symptoms from the cataract interfere with the patient's ability to meet his or her needs of daily living. Surgery is typically on an outpatient basis under local anesthesia and monitored sedation. Sub-Tenon's infusion may be the best route for anesthesia administration. Small incision surgery, involving phacoemulsification of the lens and implantation of a synthetic intraocular lens, is commonly performed in developed countries. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Indications for surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgical technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are typically seen on the first post-operative day and then one week and one month post surgery. Most surgeons advise restricted physical activity for days to weeks, though there is scant evidence basis for this. The final prescription for glasses is determined at one to three months. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infrequent complications include endophthalmitis, lens",
"      <span class=\"nowrap\">",
"       malposition/dislocation,",
"      </span>",
"      cystoid macular edema, and retinal detachment. An association exists between cataract surgery and age-related macular degeneration, but causality is not known. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Complications and outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/1\">",
"      Thylefors B, N&eacute;grel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull World Health Organ 1995; 73:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/2\">",
"      Asbell PA, Dualan I, Mindel J, et al. Age-related cataract. Lancet 2005; 365:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/3\">",
"      Thylefors B. The World Health Organization's programme for the prevention of blindness. Int Ophthalmol 1990; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/4\">",
"      Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/5\">",
"      Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004; 122:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/6\">",
"      Kanthan GL, Wang JJ, Rochtchina E, et al. Ten-year incidence of age-related cataract and cataract surgery in an older Australian population. The Blue Mountains Eye Study. Ophthalmology 2008; 115:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/7\">",
"      Klein BE, Klein R, Lee KE. Incidence of age-related cataract over a 10-year interval: the Beaver Dam Eye Study. Ophthalmology 2002; 109:2052.",
"     </a>",
"    </li>",
"    <li>",
"     Kuszak JR, Deutsch TA, Brown HG. Anatomy of aged and senile cataractous lens. In: Principles and Practice of Ophthalmology, Albert DM, Jakobiec FA.  (Eds), WB Saunders Company, Philadelphia 1994. p.564.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/9\">",
"      West SK, Valmadrid CT. Epidemiology of risk factors for age-related cataract. Surv Ophthalmol 1995; 39:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/10\">",
"      Lindblad BE, H&aring;kansson N, Philipson B, Wolk A. Metabolic syndrome components in relation to risk of cataract extraction: a prospective cohort study of women. Ophthalmology 2008; 115:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/11\">",
"      West S. Does smoke get in your eyes? JAMA 1992; 268:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/12\">",
"      West SK, Duncan DD, Mu&ntilde;oz B, et al. Sunlight exposure and risk of lens opacities in a population-based study: the Salisbury Eye Evaluation project. JAMA 1998; 280:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/13\">",
"      Christen WG, Glynn RJ, Ajani UA, et al. Smoking cessation and risk of age-related cataract in men. JAMA 2000; 284:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/14\">",
"      Schaumberg DA, Mendes F, Balaram M, et al. Accumulated lead exposure and risk of age-related cataract in men. JAMA 2004; 292:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/15\">",
"      Mares JA, Voland R, Adler R, et al. Healthy diets and the subsequent prevalence of nuclear cataract in women. Arch Ophthalmol 2010; 128:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/16\">",
"      Moeller SM, Voland R, Tinker L, et al. Associations between age-related nuclear cataract and lutein and zeaxanthin in the diet and serum in the Carotenoids in the Age-Related Eye Disease Study, an Ancillary Study of the Women's Health Initiative. Arch Ophthalmol 2008; 126:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/17\">",
"      Schaumberg DA, Liu S, Seddon JM, et al. Dietary glycemic load and risk of age-related cataract. Am J Clin Nutr 2004; 80:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/18\">",
"      Mathew MC, Ervin AM, Tao J, Davis RM. Antioxidant vitamin supplementation for preventing and slowing the progression of age-related cataract. Cochrane Database Syst Rev 2012; 6:CD004567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/19\">",
"      Vitamins for cataract prevention. Med Lett Drugs Ther 2008; 50:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/20\">",
"      Greenberg PB, Liu J, Wu WC, et al. Predictors of mortality within 90 days of cataract surgery. Ophthalmology 2010; 117:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/21\">",
"      Keay L, Lindsley K, Tielsch J, et al. Routine preoperative medical testing for cataract surgery. Cochrane Database Syst Rev 2012; 3:CD007293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/22\">",
"      Schein OD, Katz J, Bass EB, et al. The value of routine preoperative medical testing before cataract surgery. Study of Medical Testing for Cataract Surgery. N Engl J Med 2000; 342:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/23\">",
"      Backer CL, Tinker JH, Robertson DM, Vlietstra RE. Myocardial reinfarction following local anesthesia for ophthalmic surgery. Anesth Analg 1980; 59:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/24\">",
"      Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/25\">",
"      Katz J, Feldman MA, Bass EB, et al. Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 2003; 110:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/26\">",
"      Lumme P, Laatikainen LT. Risk factors for intraoperative and early postoperative complications in extracapsular cataract surgery. Eur J Ophthalmol 1994; 4:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/27\">",
"      Hall DL, Steen WH Jr, Drummond JW, Byrd WA. Anticoagulants and cataract surgery. Ophthalmic Surg 1988; 19:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/28\">",
"      McMahan LB. Anticoagulants and cataract surgery. J Cataract Refract Surg 1988; 14:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/29\">",
"      Gainey SP, Robertson DM, Fay W, Ilstrup D. Ocular surgery on patients receiving long-term warfarin therapy. Am J Ophthalmol 1989; 108:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/30\">",
"      Barequet IS, Sachs D, Priel A, et al. Phacoemulsification of cataract in patients receiving Coumadin therapy: ocular and hematologic risk assessment. Am J Ophthalmol 2007; 144:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/31\">",
"      Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005; 31:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/32\">",
"      Schwinn DA, Afshari NA. Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg? Ophthalmology 2005; 112:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/33\">",
"      Oshika T, Ohashi Y, Inamura M, et al. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. Am J Ophthalmol 2007; 143:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/34\">",
"      Bell CM, Hatch WV, Fischer HD, et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA 2009; 301:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/35\">",
"      Chang DF, Osher RH, Wang L, Koch DD. Prospective multicenter evaluation of cataract surgery in patients taking tamsulosin (Flomax). Ophthalmology 2007; 114:957.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2005/safety05.htm#Flomax (Accessed on December 05, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/37\">",
"      Neff KD, Sandoval HP, Fern&aacute;ndez de Castro LE, et al. Factors associated with intraoperative floppy iris syndrome. Ophthalmology 2009; 116:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/38\">",
"      Clark A, Morlet N, Ng JQ, et al. Whole population trends in complications of cataract surgery over 22 years in Western Australia. Ophthalmology 2011; 118:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/39\">",
"      Bass EB, Wills S, Scott IU, et al. Preference values for visual states in patients planning to undergo cataract surgery. Med Decis Making 1997; 17:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/40\">",
"      Laidlaw DA, Harrad RA, Hopper CD, et al. Randomised trial of effectiveness of second eye cataract surgery. Lancet 1998; 352:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/41\">",
"      Tan AC, Tay WT, Zheng YF, et al. The impact of bilateral or unilateral cataract surgery on visual functioning: when does second eye cataract surgery benefit patients? Br J Ophthalmol 2012; 96:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/42\">",
"      Busbee BG, Brown MM, Brown GC, Sharma S. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003; 110:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/43\">",
"      Woodcock M, Shah S, Smith RJ. Recent advances in customising cataract surgery. BMJ 2004; 328:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/44\">",
"      Hamed WW, Fedorowicz Z. Day care versus in-patient surgery for age-related cataract. Cochrane Database Syst Rev 2004; :CD004242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/45\">",
"      Eke T, Thompson JR. Serious complications of local anaesthesia for cataract surgery: a 1 year national survey in the United Kingdom. Br J Ophthalmol 2007; 91:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/46\">",
"      Davison M, Padroni S, Bunce C, R&uuml;schen H. Sub-Tenon's anaesthesia versus topical anaesthesia for cataract surgery. Cochrane Database Syst Rev 2007; :CD006291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/47\">",
"      Zhao LQ, Zhu H, Zhao PQ, et al. Topical anesthesia versus regional anesthesia for cataract surgery: a meta-analysis of randomized controlled trials. Ophthalmology 2012; 119:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/48\">",
"      Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 2002; 109:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/49\">",
"      Snellingen T, Evans JR, Ravilla T, Foster A. Surgical interventions for age-related cataract. Cochrane Database Syst Rev 2002; :CD001323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/50\">",
"      Ang M, Evans JR, Mehta JS. Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract. Cochrane Database Syst Rev 2012; 4:CD008811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/51\">",
"      Ruit S, Tabin G, Chang D, et al. A prospective randomized clinical trial of phacoemulsification vs manual sutureless small-incision extracapsular cataract surgery in Nepal. Am J Ophthalmol 2007; 143:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/52\">",
"      Calladine D, Evans JR, Shah S, Leyland M. Multifocal versus monofocal intraocular lenses after cataract extraction. Cochrane Database Syst Rev 2012; 9:CD003169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/53\">",
"      Wittpenn JR, Silverstein S, Heier J, et al. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 2008; 146:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/54\">",
"      Powe NR, Schein OD, Gieser SC, et al. Synthesis of the literature on visual acuity and complications following cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. Arch Ophthalmol 1994; 112:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/55\">",
"      Erie JC, Raecker MA, Baratz KH, et al. Risk of retinal detachment after cataract extraction, 1980-2004: a population-based study. Ophthalmology 2006; 113:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/56\">",
"      Sheu SJ, Ger LP, Ho WL. Late increased risk of retinal detachment after cataract extraction. Am J Ophthalmol 2010; 149:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/57\">",
"      Ripandelli G, Scassa C, Parisi V, et al. Cataract surgery as a risk factor for retinal detachment in very highly myopic eyes. Ophthalmology 2003; 110:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/58\">",
"      Kaiser RS, Fenton GL, Tasman W, Trese MT. Adult retinopathy of prematurity: retinal complications from cataract surgery. Am J Ophthalmol 2008; 145:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/59\">",
"      Cheng JW, Wei RL, Cai JP, et al. Efficacy of different intraocular lens materials and optic edge designs in preventing posterior capsular opacification: a meta-analysis. Am J Ophthalmol 2007; 143:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/60\">",
"      Centers for Disease Control and Prevention (CDC). Toxic anterior segment syndrome after cataract surgery--Maine, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/61\">",
"      Bell CM, Hatch WV, Cernat G, Urbach DR. Surgeon volumes and selected patient outcomes in cataract surgery: a population-based analysis. Ophthalmology 2007; 114:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/62\">",
"      Schein OD, Steinberg EP, Cassard SD, et al. Predictors of outcome in patients who underwent cataract surgery. Ophthalmology 1995; 102:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/63\">",
"      Quintana JM, Arostegui I, Alberdi T, et al. Decision trees for indication of cataract surgery based on changes in visual acuity. Ophthalmology 2010; 117:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/64\">",
"      Powe NR, Tielsch JM, Schein OD, et al. Rigor of research methods in studies of the effectiveness and safety of cataract extraction with intraocular lens implantation. Cataract Patient Outcome Research Team. Arch Ophthalmol 1994; 112:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/65\">",
"      Wang JJ, Klein R, Smith W, et al. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology 2003; 110:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/66\">",
"      Dong LM, Stark WJ, Jefferys JL, et al. Progression of age-related macular degeneration after cataract surgery. Arch Ophthalmol 2009; 127:1412.",
"     </a>",
"    </li>",
"    <li>",
"     Cataract Management Guideline Panel. Cataract in Adults: Management of Functional Impairment. Clinical Practice Guideline Number 4. AHCPR Pub No. 93-0542. Public Health Service, Agency for Health Care Policy and Research; US Department of Health and Human Services, Rockville, MD 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/68\">",
"      Steinberg EP, Javitt JC, Sharkey PD, et al. The content and cost of cataract surgery. Arch Ophthalmol 1993; 111:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/69\">",
"      Busbee BG, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002; 109:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/70\">",
"      Agarwal A, Kumar DA. Cost-effectiveness of cataract surgery. Curr Opin Ophthalmol 2011; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/71\">",
"      Lansingh VC, Carter MJ, Martens M. Global cost-effectiveness of cataract surgery. Ophthalmology 2007; 114:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/72\">",
"      Tseng VL, Yu F, Lum F, Coleman AL. Risk of fractures following cataract surgery in Medicare beneficiaries. JAMA 2012; 308:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/19/2362/abstract/73\">",
"      Owsley C, McGwin G Jr, Sloane M, et al. Impact of cataract surgery on motor vehicle crash involvement by older adults. JAMA 2002; 288:841.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6904 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2362=[""].join("\n");
var outline_f2_19_2362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Secondary glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Vitamin supplementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREOPERATIVE MEDICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preoperative testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Upper respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Valvular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antithrombotic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Aspirin and other antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Alpha blockers/IFIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Surgery on second eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Complications and outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Risk of macular degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cost of surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16665471\">",
"      Cost-effectiveness of surgery and impact from population studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6904|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/4/33859\" title=\"figure 1\">",
"      Location of cataracts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6904|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/16/30990\" title=\"picture 1\">",
"      Nuclear cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/46/36590\" title=\"picture 2\">",
"      Cortical cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/25/414\" title=\"picture 3\">",
"      Posterior subcapsular cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/29/1503\" title=\"picture 4\">",
"      Immature cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/30/31200\" title=\"picture 5\">",
"      Mature cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/55/20351\" title=\"picture 6\">",
"      Hypermature cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/22/28015\" title=\"picture 7\">",
"      Aphakic spectacles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11826?source=related_link\">",
"      Patient information: Age-related vision loss (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=related_link\">",
"      Patient information: Cataracts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36504?source=related_link\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44486?source=related_link\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_19_2363="CAGE questionnaire";
var content_f2_19_2363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    CAGE questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Have you ever felt you should",
"       <strong>",
"        C",
"       </strong>",
"       ut down on your drinking?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Have people",
"       <strong>",
"        A",
"       </strong>",
"       nnoyed you by criticizing your drinking?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Have you ever felt bad or",
"       <strong>",
"        G",
"       </strong>",
"       uilty about your drinking?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Have you ever had a drink first thing in the morning to steady your nerves or to get rid of a hangover (",
"       <strong>",
"        E",
"       </strong>",
"       ye opener)?",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Scoring: Item responses on the CAGE are scored 0 or 1, with a higher score an indication of alcohol problems. A total score of 2 or greater is considered clinically significant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Ewing, JA. Detecting Alcoholism: The CAGE Questionnaire. JAMA 1984; 252:1905-1907.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2363=[""].join("\n");
var outline_f2_19_2363=null;
var title_f2_19_2364="Donor derived infections";
var content_f2_19_2364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Donor-derived infections in organ transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpesviruses - CMV, EBV, HHV6, HSV, VZV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HTLV I and II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        West Nile Virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocytic choriomeningitis virus (LCMV)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nontuberculous mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningococcus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteremia at the time of donation (many organisms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candida species (often central venous catheter-related)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspergillus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endemic mycoses (Histoplasma capsulatum, Coccidoides spp, Cryptococcus gattii)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcus neoformans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parasite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasma gondii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trypanosoma cruzi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strongyloides stercoralis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    List includes examples of potential pathogens in transplant recipients; additional donor-derived pathogens continue to be identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2364=[""].join("\n");
var outline_f2_19_2364=null;
var title_f2_19_2365="ACC AHA indication stopping ETT";
var content_f2_19_2365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Indications for terminating exercise testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Absolute indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Drop in systolic blood pressure &gt;10 mmHg from baseline, despite an increase in workload when accompanied by any other evidence of ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Moderate-to-severe angina, defined as level 2 angina, approaching level 3; the angina scale is described below",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Increasing nervous system symptoms (eg, ataxia, dizziness, or near syncope)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Signs of poor perfusion (cyanosis or pallor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Technical difficulties monitoring the ECG or systolic blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Patient's request to stop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Sustained ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; ST segment elevation (&gt;1.0 mm) in leads without diagnostic Q waves (other than V1 or aVR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"        Relative Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Drop in systolic blood pressure &ge;10 mmHg from baseline. despite an increase in workload in the absence of other evidence of ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; ST or QRS changes such as excessive ST depression (&gt;2 mm of horizontal or downsloping of ST segment depression) or marked axis shift",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Arrhythmias other than sustained ventricular tachycardia, including multifocal ventricular premature beats, ventricular triplets, supraventricular tachycardia, heart block, or bradyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Fatigue, shortness of breath, wheezing, leg cramps, or claudication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Development of bundle branch block or intraventricular conduction delay that cannot be distinguished from ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Increasing chest pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &bull;&nbsp; Hypertensive response (systolic blood pressure &gt;250 mmHg and/or diastolic blood pressure &gt;115 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Four-level angina scale for exercise tolerance testing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset of angina, mild but recognized as the usual angina-of-effort pain or discomfort with which the patient is familiar",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Same pain, moderately severe and definitely uncomfortable but still tolerable",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe anginal pain at a level that the subject will wish to stop exercising",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unbearable chest pain; the most severe pain the patient has felt",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gibbons, RJ, Balady, GJ, Bricker, JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2365=[""].join("\n");
var outline_f2_19_2365=null;
var title_f2_19_2366="Mortality after MI lower in elderly with PTCA vs fibrinolysis";
var content_f2_19_2366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57303&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Mortality in the elderly with a myocardial infarction is lower with angioplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 217px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After adjusting for age, elderly men and women with an acute myocardial infarction had a lower 30-day (8.6 versus 10.5 percent for men, p = 0.02 and 10.4 versus 15.4 perent for women, p&lt;0.001) and one-year mortality rate (13.8 versus 16.5 percent for men, p = 0.01 and 16.9 versus 21 percent for women, p = 0.02) with percutaneous transluminal coronary angioplasty (PTCA) compared with early thrombolysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Berger, AK, Schulman, KA, Gersh, BJ, et al, JAMA 1999; 282:341.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2366=[""].join("\n");
var outline_f2_19_2366=null;
var title_f2_19_2367="Value ETT Bayes theorem";
var content_f2_19_2367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calculation of probability of coronary artery disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 371px; background-image: url(data:image/gif;base64,R0lGODlhggFzAdUAAP///wAAAICAgEBAQMDAwBAQEKCgoP+AgP9/fyAgIDAwMNDQ0HBwcFBQULCwsODg4PDw8GBgYJCQkP/AwB8fH39/f/8/Px8AAH8/P5+fn7+AgIBAQA8PD++AgKBgYD8/P58fH+9/f5+AgJ9/f18AAO9wcK+vr9+AgD8wMJ8gIIAwMH8vL8/Pz4AQEE8vL99/f68wMC8AAIBwcI9QUE8PD59AQG8/P7+/v68AAA8AAE8gIDAQEG9vb69wcD8vL69vbyH5BAAAAAAALAAAAACCAXMBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqAALBA9CBK+vaQsDBkUDDIoGAwupvWQLBQECQgHFxWkEwkUBA2kCAQRaAwGuAq2+2F8KxcMAxbBFEt0CEgAQAgMNDgAPEQO3EAAG1hLXQxAMAxG8yeP6zEXy6eOF752Ac7UeCFgnYB6tBQ0axCMggEDEBQ+mRahVcJ+QhugMQJTIzh08AgmEvbJmTsK7ctliUhFQgIEyb8waRCMSIcCC/wUBIgBQUEDAtlUDBPQUOi3YziFEjRZ40A+AzQbPmhFJIIBBgQQAEhRlAFYsAAkBahUjGiDBNqFZaRZYkFIBrqhEW60N5jYoAAJJlxoIRutZtGkMvMpcDAWog2fdsPacSiRZYp9AAysz4A7gtHg4mQHF5SCAhKpfiWkdQiBfMAAFCkRg+cwBUdUADHtrptsmRWiqApA2vTs3cIDyOjeb9hEaUKHsGEtn8szYTSHTngoR6/YvMwHgWwtPtpyaq1erlPWrihy5kNLqtqlqkHLqgwDbcBXXDVC3Yd1Vscfbcc3YxAB5ADBn3CvXTecgElQRsBRVCigVQAGgDVEdTLEZQP+ABLoE4IABnplnxFcW+VTVNCO6Z9xCKSXo4TS8TOMTbvwNKIEDsb0YDYoN3NgfgQmKSGJ5DiygW2wO2Pbgk0dAxs42+PFSxH0BgAZRMQkkSViJSCywTQK1VEUXMy5CMGaMQbZVizz4DTFkNEOmlAAvD6TUgCpjvjlnccCg2QyPpum2pYtQJvpEadDpYdObS+im6KR8BKkdHrFlqISklHbq6aeghirqqJHkY4SpXqBahC5WGgERLaTGqsc8uBX5Ba1GcFqEWBUxUZWswObmkEgRTdTASx8Z4FIEmpLDTq+PPUAriVxlJOJFRCjkQD7ddNSqEPM8UA+uDhwbwW/RiJP/IbXD6JLOOn+5s09PSZmTj0fCKqmKOw1AGuxie7X1Vm6zTaMWfik1CkCQEJC4523M2VTALtP0BRZrxQwQTC14UTZEU9Aw57AAWP2XFhESN9MAAwKkRBV+6BjVVjMd6xVMAPdVGMGe/zL2J0AQSNDANsMA7SKJ5W4DgV8KIqegfBgPU5oAowFQGkzYZZn1WTDXAplfy2il0AAppXjNy8NUfbU3CggBVAIMSKBpz9n8THMBEqBVtFYu3vdoUCLaWpzgCrqinkqHd7P14ugUw3JbiBb3QAEKcBayid4NE6Ay7jmgcZx0y2S3NwmIt3etUF1YpNZNl27t4oZrrgyQN35s/yJzEhw48rXEEQFQMjplh9a54QWgDmylB8kLchI6QECPocc0Oolonj74EGjtmT3jxcxiXuGZhy+mm7bcTo0DKRl/DjQQBPMtcpNtE03LF67TFJ/kD/4AlQp8G/3/AAygAAdIwAIaMFTgOaACK5HABToQEg18oAQXEcEJWtAQFbygBgORwQ16kA8dDBMrzgMONMzCXwnSDyJY9cFDhNBVweiGdTBXhl/JaTVm0JUVFEQRe7RwEC8sApVkCI1YEEEcHynHOd5VkncwIB7hqkcRvBW+3PwDh1Z5h0cKkhSEPIshwxrJRCpyEWttxF4DSVZIxNjEk6SkIj1sCbJYs5Bihf8EXO84HkUc4A54/VAMQdRQTW6SMZ0UoSc/8QteVKQZplwIOESoWVWukpVddSU1vCJLWArAtYOxpS9w+U5szmSXoRQlLzj55MAAY6GNEGYewEGMYjR0oW1QLhitWBn9FHIhG/nwj14IZHAecxPJXMiHlrFJIjXTLuUUCTTG2IVwrGYa1FwMUa35HGxkQxsR3WY/ROoNNAw1zbWNLjnTKE9zCPAcIfgwRwt6FtnGCRzfADMMwqyOMRRXpEtxp23kAU9FDISgwsEiPbKrCOf4hkP42IYaEKnPA3I2TXDSaUDzo2c0Nnc6eBIUTAuyIRHgaZjJVa4n6IrnPb8gzAhNiAD/OrvQ3DYkhA59KEQtUucRaIfQIuV0pMJAHzVoAZgb2chKo3vGjnoEmR8lT0gYLQ6LjuRTJQGHSU6i5UVDaryiplSHK9WCMGk5jP2txX/sKIaW2tSlQKVTcK7qk/hS8tZ7rIkabH0TidqGo3BC7k7s0BP+yNTXrboVIIQSB3AOhUOSAid+GlVpWLkwVikwig+PagJYJxuKykbBUnzIlGYhyVlSeLa0qN3CaVPLWiusdlW7gC1asaPCMKgqCbe1LRabcEI0wMKIv73UL2BFhFuA6rWVYYmCNnu9MIAPCc9NAnOZEF0mKES4YpghMayDjAY1l1LCnEc8GqIKOFoDJSpR/2ofw7YsCHhRW9rKB7zakcYotsIAx3oii7B1FiYKziLwQGNSzJgQefHCvv093n/zO8ZySeSO1/3LsQaAtS98w4gXvhQSc6NEdByPvgFGMBGo+Ct00KsIIHlIsSQ8x4a0dxTCRIsD7sNJZRpmMMyA5cSK4cO1JGyTnUwGV45iUrkUySnPwErpKjYmqwgnSPY7n/Gussmu3KkuDChyj0AmHgZA2VbwofIzKFdLXFZFKY1DIRcKuRM2HxIzijwlI1t5ZNIKQZLKoCSiAgZKgqU5lT8WRUuFIwH5KQAsulluPe1stAHZhpNVmdrwGldU0KTGHBB4GjUoZw7j2SpI4IlRbP9m0wrdTDo7n6lp25a2J+aAmn7xnFNVgjY073LBmJTBNTKFo8zMWKiZb011aKQ5nNPM7ppYHB2tiVacpe22E2N1yy0U0BNcJNo8/mE0Q9Oan/D14xmzAc/rUEc4arRHndMQaNroc8xsh9sahTu3rdIt0FhjtCpEyZutvZCd4tp5k90JaHg+qtO/oIejAiK3RYuTb70NLnLQ5icSbOKT6jAkliKyaka1I+/V8SMoMIWzApzHAO8NIUinCd738CoipdoqewTgo4yKatWKAGXkrTG5EKDsctx1VeaOZVDRSmeTYTQAQ1yAqYUwpPTJzLQYHCqAh0A0VZCe6Kk9rXqyowr/kLaY7uHP5sRYgcJJsq/TasFQ7MZ9t2048VXIF3rTQ/EzbnNEgC/jZg4EglQTxqVvT3kNrKfnroC67/1C+lnu3+3N1XZlbHYKy4JZqzSlsxoBS2vlkpcEBdcijI+wZqLrnrneDOqlG+wwlvgaMlvFUwDll2u4bFiR6wXRtt4Uj4kDaGev+tb6XrW9/73wXRv8IfS2DrkdQ/LdBivjHsH5gWAhEaSPBegvwfpVOD4ohClSadAwCrgyQ3XDR94jQLwy+3ZDHBWN3c5TR81IOH8UItzZ4hsuMfWKljwOQhGLNMBKAPZE+VIRb7RRDLZ/DkYQAtEu3bAA7iCAe7ReE6dF/wdWR//3HukQIyPGL8pAXgBGYaoRM0KwRMdDL93gLjBRLvrQflUgXsJSXitBFQWoXgPgR39RgBvmLPMAGMzygvEyECAmgIjiLnq0EBI4EuIWYfOQgCwGgpTAfRmzMSRSDqkRFz0SZp72SGnxSljYagLTFlWmScyhZW0zZr6EBFzhFWDBZGBYGhWiganDAD3RUQVzMoiHcqYkM59XIE9mGiODFV0gYzTmZBqHY4XRSzw2BIZoOYnkSBFAZb8DM0nBSkvxXbrkMmbIY5NTFNmxIl+IaHUIf40AhVIjDO0zcsQhTikSaubGV4LzajGiadtEai8XODa2aO2XTa8hi0HSCv/g004Jt2wL1WnSxEy/8hXgwQxoUSGiaAV+U2jQcGjxxH5Oph08xGtGZR7yARC96E7o1HVYNDZlo4rP4DVFpAyyKIz2pwikGD49oTTxZBj0lkDuoSDzOAz2CFHsNhXMkW1f9W/vYTwPVW4EGTXhAxANN4y7IXBwREhcAR5eYyO1pQXSxgDUNk3Xdna6Ujj/tDjMYXVOdiDgmC2UYzn/eJKeuDUJuY6J0I6b42nGsVScBHMyV48ZR5OOtDVERSPMARQ6YRb+CBuNFVSxuHIvIlQjhiJFVxxet5T4ISHEYVMgAjzrAGoEMA+5c5UwyQUUZ1WBc21JEpS2kyTG0TvCk4X/zTA8FNE4P+UiwONV/ggfXpWSttKU6ccILnkTKQEvz2AnVkI/aDkEiZUbi5ePC8MltaAgBlAXvOCPQOEvatIWRbk1mSaZNGSIw2h6nHMz+nEoXXJkdhcMRSFU6uMFZmd28ZRYYvkeaZdWWlMkdBUPyEE/BbB5b4UokHWSTkZmQkeQmsmSiEB7S3MxkmUHEkCcPSN77lcGp/FQc7N9wGkEDnd2eLAQ0bN7y0kG6TNypkB7w/eduRKdwuednEWepWWevEdZ4llA6LlS7TlS60lA7wlM8/kR8TlA9flD+ZmfwMKfH7Sf9wlA6VMMnASe4ameHtQTxsAzBgqfCLpB1AN1/0vQJK0FoB6EJd2TBIc3keUZoNLlof9DJcgZDrLBMgPETvcwDwaQIY8hRdQBolECo6FDcZHnTmQzPzKaKFa1GtswDXxlE0ThMZuSow7qQaVxMihWE6Dhn4xhI1oBH4fpAEszkxVFR+qGDgPAglLApKSSiManAP1TpACEIC/iI5GIRTGjbu+gpVHApaMyAK64PqrnpjJBplLSVGeKYhJnof+pHygxALCXG0QKJWSKFrhgExJwc9TEoPappw/qQQsgpV5RYY4KQAuwjAQAAfdROi4TFryDQhnEpx5kAF7RAIGqIYP6IDbyDfJgJ28yPn1Xqaj6qBo0PDaIBHTan3uaqv+CCqEJkAAecADCegATgFu8Gj2hyqsdtArXEFyyQFwfw6FkkHzLdyu/WgsHYAEIgAAWcABJUIPpKaZZkEGBQkTG0F0SJ39hgCtO831doBAlOQQHgABCgADeigQKwKYXlKy0OhTcsF0lhD3j0GFMFIRQRA+/RGI3YWKIkmLEQhIfCBMupg/NUg4RFi3T0hbwdi0XmHRLcSnzWq/3an7P2UL8CnwjNUhElA6XgkjttEhIQWdcJkSnNBWTZDyV5Dv4wRcDg2YGA2hgs3NZ4jCmZCsp4z0WswUGEBWBGrIAYK9IsDSTdbJipTiOISULs3S7dhnL9GvfWB7QlDFqU03HpnD/yiY0zNZo03ctSsM05tGud+auUrCYhJUETgu1RwBTU7urj6pP/2o7/vQVAPUdAzceVndQCKeQo8d4K4l6Q+A3aQE4UVYrhmkFdNuM8kqvTzuyReA5eyur46o4LhUUFLJ0T9c7UolTVDV+POWJP8V2jGeX1oMotrQ68dA6rFC5U3C5TnC3nDtS0mqyfIuyKKYMkxemV6JWbsNWtgmSRPB5ZaIMZ1JXN8R4v+m42ONp2yM41aFz47cEvPsEvjtxx4qsw1u1VqCcMnEOboG5SDC+z3erf0S1oWsF2JkN7VAAhjQF8GsE+fq54ooFuUoKFiEbp9q7mou3RvCa7nm+9Rsr/0vLFSUbBf07YnIrvKArwLxKfUrAwacSdrcSW10AGHWbBRXMGq7YwBl8BYHUfUoQR9QBkP4mBd/7wiyxBQ9wdMd6whjYoStMfChDgQBggkqyUVTTf9gSR0GDLALhETqEX/CwXx2Lgm7DLx5SgI+7EPIlBE3MD7ShLBQ7BfggHBNsBTycG8GLwQHMwvyUhqkxJoDqab1ohZx0bYnBSW6MaHaWZC1TVElrICiXM0rRL6+EMUN2I3kcawgTtE9AE6YKBmccAZRKnw6swZXhGtTwK9NwH3tCjs4BNq2gi9SgK5fmXrKIjFnxNnFzuzQUaeqByYznbFCwmFkqBmf8vwA8q//Eu6gD+St79ZXAYTK9GZDxMcraNsN1+ZDk5TnB0DbPxVEOJR/w9F1R2zKVQwZnfMFqrMvo2xwwkskCaQ6i2RwyGU9YVSFEaczagXIWUVRbY5U7GAHOs2UZhzHnchSQgZTTrK4lob/6qgU8rLc+vMZAPIJ3lTUFWm3N4ZfxxFiR+avqvIF4Z5gQcHcXYg38wwuDaTj1wREHvc8gXMARcMBfwMMSUKOU/MNVsFrbcA3TNQcunL6HdhBqwMOSfJ6VzMZPkBlaxQcxPQUZIXVtwMO4nMuNusvZQBMCONQJ/LvegFr0a8nZAFNFzdQiWwQCPdDc/MC9gA9FIQcnfNJQndP/BY0KpDoxJJ0GJ9wvY63SM1G+ikDCDCC/b3DCONPWBL3ScN3NaZC/NG0HFZxVOO3WUzDAep0G52DAeVDBs5FaUa3T1bnXSEDL/+wGFQxYeL3VUn0Hhv0XZOO+YN3UxjeiRt2rSF0HA+zXZVwH/asUwMIAb7JhYPDYZW0HdJrYIw0I/cudpAIBMHUuAAZIZH3YkR0G6FPLgQC/9yEryTBDKJ0E4lJ+5qCiz0nbxM3ZcJ0RJZzcoi0PjCoqCpEASUEOq+15sdGjceujB5rXb50H/qnU5a0H8AutsYIRhT1NxwClXzZS4y1Qa3radJCffzpbui3a9xHflPIqTrTTwRAk/+Y4DFirIf0NHv/N17Y9qBWNN4kwvmIdLAPKz9lyaMEQShDuXdbd3sWNBRIgGwjeB+P7mcGylVBgKRBQNobqZJR64oUt2ZtNBbNQOozgu8DQMyszBUtBKBPldZ0awKJ64VXg1TzOBr6bGD1zd++AfUpwePgBL4uZP0yurFFe21Bw3GlNCL47Fz2zqiAu5k2O2gHqFXStCHcLA6Sd2Udt4W4+f2Ba5oZwtyQwybFSEBAR53je5gG+njySxovgtCFw10T+DTsj3IS9pWF+3UwA55XgtCOQwjHuEhQBwlx956Ge59a155bgtBQgAqEjIlmaDpLO3jvu3iyZ6JgQshlwAf9OLSt39xVIOtvDjeJ18OEFegSYXuv0SgEgkOuBzneKPuqGHgcKWgzf7U6mngnzmgEUoMD/knsKQeCFDuZ3EKG9QwS0vgnzSgEZoO0e3g2ujk+/Hut2gKG1gz212QkHAAIUsLmrvhPo8OqaDdl2IKKHhNmcoAEX8AEVgAEaEDoJwCxq8tzf3q9zQKN2pQAtHgl+W+ndaR2VDeyi3uN0cKSv2vCh8OEabwq6oGDuPultevJSkIg8AuiaIO53OSoGANoRD+BzAKdnUe8lb/Khcyw59O6U7t5ySPCfsJgZHzqLeVD+/vEAbwfJYPGjQCZLTzdqDuog/+xxQBcQvwmLWZb/f9sz8yBQOG/ppo3ncjAYMt8JhHX1dOPbcv/0aT/qcUAiwSqsxQoKYS/2NS8q1ANTzR71dQ/ycEAiBpCt3KrsmVC3cP8vblE6/b7ysF70c4D4ABCy6g72xPn4MQ4Y2UT3XL8GmJ/59Lr5mlDCng8sDV8hserrLA8F7fkY1hkhv+UEpW/6+u4Jfd8c+xQ6R3pMog/u1tV7kQmnwuC3x8AEua/7qI8J2736wKIkLkr5/y7mSJAMUVJRkUoVmKqvze/8jF8Jve/7Y/8vBaHysF/5Ld8E2m8Epkc1GKP1biPURaD54z8J7XOr0g8EAOGQWDQekUnlktl0PpmDwDTggF4B/wJBUYtVdpVSamBLFBSoBiEhMGA+CmrjAQFAHLx5/X7JaBgFxsr4CAsND5nIACAU3BC5BoXADCeRFggkAggIHogghBYY2tZGlRgjkOjs8B5bXQEICjq5BF9tb3GLGqyy/mwrsyIJgZHYjgQGDAgiFGFLkxRQU+vucq29EiSOa6+7vfUiEgYGEsQZXoGJ99SNFhyLCMQSBtnejyIUPqdXv/uRkP9x8zeQYBExY+whSieMDztcDPIpUVWtoL8FARYEpMKwYkePjxYq5IjLQIGMEqmx+nhtwMgsAlfGlDnkgQQBciAYuKnPjDCHXn66cmCSyUSVM19JSPAFJlKnBQ0EKP8wwJeCNgEUAPLpEijXVgviNDH61BUcAkw3klXr70GABDwdBPjToAoku4eCIgIrp2jKtYganEM7xetfw4YyKUCjLdCWxlxaatEy7iylwoYYCRbr9zCfoTw1Eu48usmyyk0CRRga4MHjx2YiS6aM9zKhU1DGkvYCIQGvwc10By9ysc3JJZm2SMEU4JwobT3vWrbWIGFffsKhAGQSKC1272tuNmnbu0ABCOMJJGAdXVJtJ3kJ4QO9+fr3JW1nLeEu2v7o1gJOe8IA9RI4aUC3+BoiJNpwEeAtLHLrL4mW3mtKQrKiokKaX7YS6ZaSjMONswuNcOBB1CwkcabxGEAmgAT/W1lQuleGClHE+lQUgjfftksxx28oBMAPIiQwbwiqbpGxEPi8gAPGGyn6MYvqfnNPykdaE0eLRmDrkkP2hrESigE08yLCHPHLzscrcWFjDOCymGoccqhkEDo7QYpIjzNVDPKJ/eBk8xoICIhmExsBnaLOGRUUUz9HmYjFRghHVNHE+XrsTtBvFshIAhgf2ERUAib18E5GMcuGED4lhKAAHivUdNNuFGhxCliLcOA5dDrE05AGfOGD1f4G2FBNWWe1RpMBFAD2iCyfcUXJMBFRClMzK5XQWqDWTNaVKpjTTkcDDkrgSVMbRZcQsALcY1jv2M0DUEi9zYOuF51VcIoE/0RpN8ZeUd2DEXqPeBc7BQiet95rHggMggF4DMRcCDRpEOAlCS6CgUWxxdE+AbLSQ+GFrSHUZCIWiACNKXblFcyGMh5iqPwKMVg3SdfplmRDMiy0zHHF4JjaUzG27dVHbB6Nt5a5RXbnVhJQIAECxDXiAQaM/ffldWIGoNhWku4sAqFRdPppRJYlYGMiWquMapq1JnpoPbZFOlvhPhtG57P3SACfM8oURR+Kfwbp4rm9iBfsu3VzFdem+eO7lbimkIWIcS4nm+utRc4Y4VfC/mvtJfeWPI8FBJAAbnKIECfJw2EWOWRXQlcrFrhFLt30KxiQwyYz5NqErsLVDab4J/9wBp3x0T6nRPfdmyDUUAKo88QqKoz8Uu7YsVj6ltqfAlmh56Ffws0xsoZAgnEYuLZ4Jt+DdGxcwEfKrPHNLh+LLCOTwP1rpsU9KOTte8szDJlAQj79KUEZoMCdNwK4OSiA5XF281hnCIgXBS4QCUGqWj8i2DkoDMwa9YuJ42K0QQ6ibAAFEEcL7TGATj1QWrCToBPylQsTrgSBKczfCkvzpqMNoQp+shjn5OUekP3PglHqjAT0lMAfArEJvUOCet6kORFu74ZLqFE3dtiRi5SKdFOk4hIMYAAINCBrC2iAC+dEPF8Zb46WGOI1wlgQRjANf5E74xWywYwA8LGB1gj/YRKZQEJv5JEgo0OHCv+oiUY4EmWpo+Ec4YeawuQQjAZESgalBckzFqAxHwRAhqRCxoBlcjteWWI/GNkPCjZIlFQUhSSzBoACNIAADmjW65DYFSV8EZaePGHzklRLIKrPARAQwKQqNiVgcnGLR9jRQGLpDU7+QplARJ3qjiA1ATCgAHJcZdeoKU1sGvMjr8zFyP54BVQSZTgri2INg4kFdqRpnRecSVzQWTY/xtMJu+zlL49AqnfasJoGCWgesmkNZpwrlGYkqBGiaUpCbGJwOlGjVvJ5BXVcqiARJcmLugHPizZBnOQ0Zx56JgSrSGF26UqnMItwzZKyEyooTWk3/zkIlinckxBwmMJZ4jKXusiNlY8ChBYL6M+PRIWi3LToSuFBRgIwMQzjqJhrAoUMyUxmAP5qKAD4uVOpdoSqIASq/lrjvwkVIAKqREKRHqCclzgmrLEhq1kRebmHuoun/WirW6+6UqNKxX0GuF42uHqkNy2nOYMEU1O/EAmSdsSkjzgsYgeK1SNkggHOUUIsrnqJQg3yPG5Jz3qYOthJoNAjnT3EZ0EbKNE+VQhGJIJj9xUOqHotmgcyF0hvqs9BULIiti0EbnM7WNOdYRxwLJwUVDMEu3aRjjO63UqcywfoRne3v1GUEbYKQIZiAYuVQ2ZtC5uLvXREpeUtQqhGpf9QhwphSNqzaXzeVFP4rtUbrqoqBN96Uf5tabjKDakTUHlUmYR3N9FoZ4IJer7EBva/fGgLFV7aTycOZJsFqa99nyC9CBzqiMmFwvWyFxMKX0E+KzkxipFySCzcMpcDHvE3ShJZBG8Yx0SMB0Km2WHPTOHABJkxhOlpYwzHU4Ybi2OS23OIW15SrT++xnjpO+Uix03JeZhAD3JwgR0cYAIzeTIafSqTG485CWOVTJMFmGVCdOACP8CADSxwlI+8OQlg9sic6XyEN53Xv3rmgww+AAAWmMDLzY0vz+I8E0QnGh751a/LXPyGALxgCJXusqBPimcTi5nTRQv1EgbQgjr/CMHUTr60eDOdY1ZTcVlIbnR382CiEsyawCJG9SsMHZNNt7q3oZhTD0Fd5hH2RhW0Prali22I+a5l2cwG4XpR44ZqZ7uY5OaDgQ3TbW8vwCrlbLG0nZCmcdfa2Li4Tbp3fUb1MEu37yNYkOZ97VPjosRkUTezl1q9X2MWAJsNuJtvTWOiquXgrbZiL7AMbCgcVwgPn3DEBRRjfBN5zIuOFpkdDYUBEcHjMgZ5E0BEmorT+dlXXjikON5xYtPbHzNOtsHz7W2cwpuBS2H5zgVua3OrPNeHmXmiS0KFBosU3FeEUcvB+/JCN93pQQdiOdpA14yzcuVFwPqgtX6En3Pb/+srBJeQeoxJMeV8CGf3cdLlyfXOPJ3OkhSAwqOdciaU3exIh/jS4axqiredg9HgTojzrPEl0L3uhv844reu+MWTvNUS4KPhHiwEwhe+1HjvedpFr3eZM56DDrDkuwWvBMpXvvSH53niJcT3Md8ylWOvzehJb23bm56BqteN7oscvKEEC5+vnj3thX/52yNh7avn/JinJompZ6fqojf6PqLvcswPofrWD63QG0WdyTCfCagLz7h2glyit+7AducsyMtv/n6jHwAmH+4YBGOmsEL+Ys8IgG8OLE/8pu+3jA87kM++PO3TYA4AiKPh5AIA6AJWdEwInu/oak/6iI8BNf9P/6RrpSQQCsZjr1QwttDo+5LA/rBtAU+pAb3jAVFMqLBCyHShLsDqcIKiAz0w/LJu6fJPOGzQvsphnMQuxaTAd5hDSCwLNuxsNu5KwMBv/HSosIrQCFlPfzIKqh5gprTgAdBDPeBGrMaKCo3AVQAr+LCQfnhqC7nw+oosAXjJl+IuoSbrlAjkSQ5JowomAYeQ3tYoLDblCMtrnrYr8tiBDZ0ABgcuCZZPB9tBC9QIv0ZF1+iwyL6Jy1wN3iIgDxHwAxXw2gqxgpqAGRqhDRIlADTx/PiPvyDvnJ4FtuhDCNHOnyZRD9ggZNQnVBJjE15x/2JxfgzJhkLxRnDx7oz/gJxQMd6GigF8ox7CpwvLp0juzPfQS+SsYxnvD0fCUAE8kRYkTGbaSxqo0SkQcbcO4uRAb3t8qxvfMKqiZChm8b5EhSf04QEyhBS2D4CsEXpUi8VuDh64UR5lEI84wxkPIT0kYDkcIR2HsQQJyvXASRuJQAE+bwkgUenuIBzHEQXfSCoiQB8kUtMCcnd4L8qar8MO8Bbn0RYmogbcbXfWUbSUb5cwkgNHEPpiUnluwAd6o3xuEqsUoDIAkRa9D6IE8SNOgAY4YAVCMFmKcqU2hqzeD+W6Cwg5sikrAgJEgQN4AAM2oA1Jpiovqh0ZTSvB4CUf0SsJ4gxWZhNzBC0J/2ogRWUROay9pIIru5IUoUIcqOZNKHIOYTEWIWgQBIkKXJBSALMfnKkc5CBRCjM47BIxqY783qQn3TAhD+FqpiJAKJMoUxIzT+XDqIASA/ExrSFlAqCuAIEwSZMuTTPPrucCCYs1byEeyomGRhN6LrM2NYkIeI8zO3MqxSsJmeg3bbI0hbMSKCcAVHM1vRERQFMBVI05p8s5axMY1nJP4NIQHIAuYDNWaJNEglM4nepylio3q1NglAKyREo2gZM7TRMYmIspdVMPXHMX5IU+m/M81dPBaKI93fMnh6BQejNn7BMlBXRAuU8IJuAAUEAFDoDNhCU8n2ABoCh49KZB5f8MRGMRDA4AByggBBAg0DJ0PyOFARKArprJeURUyh4UQuOn4y4gA97zLVnUmhxAZfjFLP9zRi+sRm20lYRABCigR2Hy9jiULjRSL4fUSL8jPY/0LhJgBJgUIQXuScujAQwgJBsCQLeTSq/0H7bAAC5AQ3kUF710lyRASmXUTB2QSIWuCxIgBdi0SfHgTRsgTgdCOyXHSs+0PQakI5tAAzCgAhgVA3TgSwG1IgSVbwi1ULXAXBCVCXgvAGJgBuTUkMh0UO3U2xxkKTJ1DTFhJMdgA9pMGL3BVcnRSGH1VYXUPIkRFmq1UPUDpU51AVyPHNogAuJ0ZBjurCQhVCNPvcr/6DAlT1fV5BNgkEPHxi1awgEQhRuKlcOAB8Oy1Vgh51a71VIdYd5KoIEg4FfdQljTq86wtTLRdBu41V3rDJ02LVzPdB6EQFEZtQJcwC3ArlopkVjllQD1JV79wV7rdWBxzCIfKCoiox1JoAMw4VO3lT/sNUJj02C/bVnBVWHtSxQUw3JypREmY1XbjEEt1mOlbVK5S1k/lFkv1tsopgAAgLSO4WERws50dmd1th0f1q94NmiFVmjHYWfVEmiHNmmLNmmZtmllA2mdNg1zNmjj0VmdwQ1OMkGjdmu5tmu99mvBNmzFdmyTNldtlBqz1mrVNkcuIiuSam3hVkrUYzxp/zBu7XY02E0q7vFu+bZv/fZvATdwBXdwE41hcyEnxlBmXq8VQsU4DNcWXE8AZuFxaSRxhYByMYMThgBxP2oRPGo6IRRky0NMc6dyOkF0RfYQGKEUUJd0R8gqFOAooTBkXRcKVBENzqJ1G5IuBkEAQ8Z3+3Zma/YJd7MTeFd4bRYRbskNkJd4H4EZdqV59/YKpsCZyEB6D6E73jYDt9dA4RZt3fEVJgp8/7EYyGAUyNcV0ICmQgV9w7cQmCFq8iF9NagMerAH+ZZ+caFtr7Z/U4UB0jdtC+GomGHF3Ld8jwMrUkl/Scd+FaGUHvhWC5V/35YkCiAiKBg3C0HDimMAK//4EdDgajOY/bRtFDJBhjxYgxtYCGzWOVo4Cu92bunCOKEgE8opPGS4bp2AUJZDATIih2l4CZhBAIYYAIC4LKTiR1/TiKtghhuygM+iDFlDimt3QPO2Jm/BZymw3aYXeUrhirs4xe5FMMDYFg6Erj6hjLN3DLwPQdrYLwk3juV4jum4ju34jvE4j/V4j/m4j/34jwE5kAV5kAkZTWzioxCIXMgI2mAtjAvZWSPMDdBXcv9B8d73T6IpUiT4kf+oLQrgLFCn/7BWclvDAa5SEuTAAKijfahnHJ4jWkp5Y6ygbRxADR5gbOoqr15TDZyJKnhhfcjkllmRk+0reYnIDQL/YRMUBQ3UYBQCoQEchGoiwEWa2R7YYB6s4hKkog3gAGHKYwHUo1YAQDFABiOYoUWO0ipch5h36zWO+SWUeQsASpR1yegg4J4loAGsYguihQ3kmQzYQDAyYZqVI5kpkBWHmC6g+Sz8mZ0T8Rk6wZk1oaEbehSiRTE8TxH6WRH8uaFfYprH0KDrQTK2Ch9uxaMdWrT27e8kGZknmqM12g3o4iF5ybVEgZ+t+TVXS5vLoG0dQG1QB6B1KQ4wwQDU1TnYwD9TGqsaZl+0QaLj2RlwehFUxi34UVFimgiuWSrUAKV9aajIUD3+wI32xfXQoCalgGaXum9Req1Tuq3dOq7l/3qu6RrqZKgPEmJt3EENGDlxqANG3M83eHhz87Ku48mgw8AVf2sLGjo84NoJXhRAiGAxm+GWeEHDCqQipMCwGUYATBli0ApAapkCx6Z9XiKfGyAjbpl9PkEKHKBYPkEnpDoL1IAZWgJ1GPqZPGFjYDMq8FUzxbHh5ACL0BF9y+NaYhm00QqXM4JqFqCBlqFYMoJcBuA5bmJ9SvK1JJuzd9Mtylmb17ebzyArAqElygMWWqKAiSsCROEPNrui3UCdB6AtlIpmyFkxrkYq7CEDc2WQ0OAT0hF69RCbMUK8zzsQ0ABAsEKsRMEPLGuo1CMCoi4ZuLu7/1nBBbouRCGoc/+3YoxaCtxgs8fZFd87qz1aCugbZZ4wLp46IfRqslljovzXnbVaEQBqoF1kMHmBLmYBDuahvOmZYkJcsSvcFigaoJvBoJNZyTWhwalRxDe7xKfao6PCKnjkyKcaxgfhASimDcLZf2UcvWBaC15TMlojmkRcCLzbEumZntO8yF2BDVYsmz36InjpRU97KGjWtR2WuJbDvV0Rvp3BP11FKozAhagHI9q8QMscYXDcQTCiFwczZKaixuccI3waqBF7oKnm7wBatkthFFybYuHcCbY6LFD6QHz4JdAgs4UKxIlrfVs70LM61oXgnNtBneXAHVcLK1ZLH5wce0ryoBPk1OVd4Kux4sxPA9JfBQKqmpTafBRWYyNLfQ8euyKsoooLQSngYZOr/SmunSAuAoHXAVbC/dvRPd3Vfd3Zvd3d/d3hPd7lfd7pvd7t/d7xPd/1fd/5vd/9/d8BPuC/IQgAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The probability of coronary artery disease (CAD) based upon a positive exercise test depends upon the pre-test probability of CAD, ie, the prevalence of CAD in the population studied. The solid black bar indicates the results for a negative test (-ST) while the red bars indicate the results for a positive test (+ST). The results of a postive exercise test are less predictive in an asymptomatic population with a low pre-test probability of CAD while they are very predictive in patients with typical angina who have a high pretest probability of CAD. The posttest probability of CAD is optimal in patients with an intermediate prevalence of CAD, eg, the 45 year old with atypical chest pain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Patterson RE, Horowitz SF. J Am Coll Cardiol 1989; 13:1653.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_19_2367=[""].join("\n");
var outline_f2_19_2367=null;
